

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
17 October 2002 (17.10.2002)

PCT

(10) International Publication Number
WO 02/080980 A1

- (51) International Patent Classification⁷: **A61K 47/48**
- (21) International Application Number: PCT/GB02/01613
- (22) International Filing Date: 3 April 2002 (03.04.2002)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
0108332.8 3 April 2001 (03.04.2001) GB
- (71) Applicant (for all designated States except US): **ISIS INNOVATION LIMITED** [GB/GB]; University Offices, Wellington Square, Oxford OX1 2JD (GB).
- (72) Inventor; and
- (75) Inventor/Applicant (for US only): **DAVIS, Ben** [GB/GB]; Dyson Perrins Laboratory, University of Oxford, Oxford OX1 3QY (GB).
- (74) Agents: **CAMPBELL, Patrick, John, Henry et al.**; J.A. Kemp & Co., 14 South Square, Gray's Inn, London WC1R 5JJ (GB).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:
— with international search report
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 02/080980 A1

(54) Title: LECTIN-DIRECTED PRODRUG DELIVERY SYSTEM

(57) Abstract: The invention provides a kit for lectin-directed prodrug delivery comprising a prodrug and a lectin-directed glycoconjugate, wherein the glycoconjugate is adapted to cleave the prodrug and thereby release the drug. The glycoconjugate generally comprises an enzyme conjugated to a carbohydrate moiety which binds to a lectin. The invention also provides novel glycoconjugates and novel methods of synthesizing prodrugs.

LECTIN-DIRECTED PRODRUG DELIVERY SYSTEM

Field of the Invention

5 The present invention relates to the targeted delivery of prodrugs to cells.

Background to the Invention

10 Increasingly, carbohydrates are being investigated as the key factors in recognition processes, particularly in cell-cell recognition.ⁱ Carbohydrates are often found as conjugates of other biomolecules, forming glycolipids and glycoproteins. The carbohydrate moiety brings its own particular functionality to these structures, increasing hydrophilicity or enhancing conformational stability.ⁱⁱ

15 Naturally occurring glycoconjugates exist as glycoforms, with slight variations in structure from one glycoform to another,ⁱⁱⁱ resulting in slight changes in physical properties. This does however lead to the desire to produce homogeneous glycoconjugates and so a number of strategies towards this goal have been developed and are known in the art, as illustrated in Table 1. Many
20 of these techniques suffer from lack of specificity and control of the extent of glycosylation depends on the length of time and concentration allowed for glycosylation to occur, ie the prevalence of a particular amino acid residue and the kinetics of the reaction between residue and glycosylating agent.

25 An improved approach gives site-directed mutagenesis and chemical modification by introducing the single free cysteine residue of bovine serum albumin (BSA) at specific sites within the peptide chain and glycosylation with cysteine selective reagents (Table 1, Entry 6).

Name	Scheme	Amino acid residue	pH	Time and extent of modification	Solvent
Reductive amination		Lysine	7	4 of 59 lys of BSA in 2 weeks	Aqueous
IME thioglycosides		Lysine	8.5	41 of 59 lys of BSA in 2 hours	Aqueous sodium borate buffer

N-acetyl glucosamines		Cysteine		1 of 1 cys in BSA in 40 minutes	Aqueous ammonium carbonate
5-nitropyridine-2-sulfonyl activated ^{iv}		Cysteine	5	1 of 1 cys in BSA in 2-15 minutes	Aqueous ammonium acetate buffer
Diethyl squarate		Lysine	9	13 of 59 lys in BSA in 16 hours	Aqueous KHCO ₃ Na ₂ B ₄ O ₇ buffer


Methanethiosulfo nates		Cysteine	5.5 — 9.5	1 of 1 mutated cys in SBL	Aqueous buffer

Table 1: Synthetic glycosylation techniques

100% delivery of any drug to its intended site of action is currently impossible. The natural metabolism of compounds, natural and foreign, in the body ensures that the drug compound is converted to a form that the body is able to excrete with greater ease. Even if a drug is designed to withstand in vivo metabolism it
5 is still essential that the drug reaches the desired target and therefore that some direction or targeting is built into the drug.

There is a need to reduce the dose administered and to cut dosage so as to prevent side effects traditionally found when dose is increased to overcome loss
10 of the drug in vivo. The blood distributes a drug around the body. Transfer from the blood to other sites of activity – the intended site of action and of elimination – is generally by diffusion and is therefore controlled by the concentration gradient between blood plasma and target cells, differential delivery of a drug to the site of action and the selectivity imposed by receptors
15 which may or may not accept the drug. Large pores in the capillary endothelia allows rapid transfer to the interstitial fluid, and thereby to the cell surface. Transfer across the lipid cell membrane is now dependant on the hydrophilic or lipophilic properties of the drug.

20 It is rare that the specific properties of a molecule required to bring about some response in vivo are also suited to the specific delivery of that molecule to the desired site in the body and crossing a lipophilic membrane.

A technique to increase the selectivity of a drug, by enhancing the ratio
25 between the activity and toxicity of a drug uses prodrugs, or Active Drug Production. Prodrugs generally consist of two moieties, one to allow uptake or to mask the toxic properties of the drug part or to protect the drug and the other to bring about some effect, which are cleaved near the site of action in preferably in quantitative yield. Other advantages of prodrug therapy include

reduction of gastrointestinal irritability and pain at injection site, improvement of taste and odour, increased chemical stability.


Enzymes found naturally in the body may be used to carry out this cleavage.

- 5 One group of strategies involves "bipartate" drug delivery, where two different moieties are independently administered. The first, normally an enzyme, specifically targets a cell type and provides a mechanism for the activation of the second, normally a prodrug. However this has been limited to specific therapies.

10

ADEPT (antibody-directed enzyme prodrug therapy also known as Antibody Directed Catalysis – ADC) involves the introduction of enzyme-antibody conjugates which are complementary to surface antigens of a target cell, followed by a prodrug which is selectively cleaved by the enzyme previously introduced.

15



Antigens are one of the few physical characteristics that differ between cells and so it is possible to target tumour cells in this way. The elegance of ADEPT is countered by the problems of controlling such a complex system.

- 20 Determining the antibody-enzyme conjugate to be used does of course depend on the antigen to be targeted and the prodrug to be delivered, but more specifically it is essential that control over the pharmacokinetics of the conjugate be controlled. The conjugate must be localised at the tumour cells before administration of the prodrug, so as to allow release of the active drug

from the parent only at the desired site. Careful modification of the antibody of choice and the gross molecular weight of the conjugate does bestow some control. The antibody should have high affinity only to the tumour cell antigen, and its covalent attachment to the enzyme should not affect either the
5 antibody or enzyme function.^v

Mammalian or non-mammalian enzyme is employed, non-mammalian reducing the risk that any enzyme present in vivo would cleave the parent prodrug, so allowing even greater control over drug concentration at the target
10 cells. But problems arise due to the immunogenicity of the foreign antibody-enzyme conjugate.^{vi} This can be circumvented by the use of mammalian enzymes, but exclusive production of active drug at the target site is unlikely.^{vii} A number of techniques^{viii} have been developed to prevent immunogenicity caused by the presence of foreign enzymes and antibodies, including the use of
15 humanised antibodies and a complete redesign of the antibody in question.

Current methodologies for the directed targeting of prodrugs are variously over-complicated, highly situation dependent, and expensive. There is therefore a need for a new targeted prodrug system.

20


The presence of lectins on the surface of cells is widely accepted and exploited. Lectins are carbohydrate-binding proteins in the form of multivalent ligands with binding sites that recognise a particular sugar residue or sequence of sugar residues. The fact that oligosaccharides are responsible for much intracellular
25 signalling, bringing about a physiological response, is also commonplace.^{ix} Lectins were first discovered in 1888, and since then their investigation has lead to a plethora of articles and reviews.^x Known is mannose directed uptake of a beneficial enzyme at a specific mannose-binding lectin on a cell (macrophage) surface.

30

Summary of the Invention

We have now surprisingly found that by a novel use of separate glycoproteins and prodrug conjugates, we can provide a protein or enzyme which is directed to a particular target, a desired cell type having a specific lectin in its membrane, by the exploitation of the specific lectin-carbohydrate interaction, and we can provide a prodrug which is directed to the enzyme, by the exploitation of enzyme affinity, and which is processed to release drug. The system is illustrated in the scheme for the enzyme naringinase.

10



In the broadest aspect of the invention there is provided a kit for lectin-directed prodrug delivery comprising a lectin-directed glycoconjugate and a corresponding prodrug wherein the glycoconjugate is adapted to cleave the prodrug, with release of drug.

15

Detailed description of the Invention

Reference herein to a glycoconjugate, more specifically a glycoprotein or glycoenzyme, is to a carbohydrate, preferably an (oligo)saccharide, also referred to herein as a sugar, which in turn is conjugated to a molecule, more specifically a protein or an enzyme capable of bringing about a specific chemical reaction. Glycosylation confers recognition as well as affecting function and transport of the protein or enzyme.

Reference herein to a prodrug is to a pharmaceutically useful molecule, hereinafter a drug, which includes a deactivating or masking group, hereinafter a cap, which renders the molecule pharmaceutically inactive, and which is capable of reaction with the glycoconjugate to remove the cap, releasing the pharmaceutically active drug.

According to the present invention therefore we have combined numerous separate, but synergic, mechanisms into one elegant lectin-enzyme activated prodrug system (LEAP) combining lectin binding for the specific targeted delivery of an enzyme to a cell type, with the controlled release of a prodrug by that enzyme which allows control over the whole delivery process

This "building block" system allows the potential construction of a diverse array of combinations of enzyme, enzyme glycosylation and prodrug, potentially allowing the selected targeting of any drug to any cell type with suitable lectins.

In one embodiment the kit according to the invention comprises one lectin-directed glycoconjugate and at more than one corresponding prodrug. In an alternative embodiment the kit according to the invention comprises more than one lectin-directed glycoconjugate and one corresponding prodrug.

- This provides an additional pick and mix type methodology for the kit adapted for the treatment of a specific condition with a range of drugs, or conversely for the treatment of a variety of conditions with a single multieffect drug, and allows a clinician to select and tailor a methodology and kit to target different tissue with the same activity or the same tissue with different activities. This can be useful for a specific individual, but also importantly to speed up treatment regimes, avoid conflict of treatments and the like in the case of a complex conditions or sensitive patients.
- 10 The site and nature of glycosylation determines the effect imparted on the protein or enzyme and glycosylation affecting enzymatic activity may be near to or distant from the active site and may be of natural or synthetic type. Glycosylation may be site specific and is of the N-glycan or O-glycan naturally occurring type, forming an aspartylglycosylamine linkage beta to a serine or
- 15 threonine residue, or is an N-acetyl or xylose linkage to serine or threonine. Synthetic type glycosylation is usually to the lysine residue but is more preferably to a cysteine residue. Glycosylation may at a single or plural sites in any given protein, and is controlled by kinetics.
- 20 There is provided a method for the selection of a kit as hereinbefore defined, comprising determining the lectin type or cell type or location to target for a given purpose and the drug type to be administered, selecting a carbohydrate recognised by and binding to the selected lectin type or cell type or location, selecting a suitable cap to form a prodrug, selecting a pharmaceutically
- 25 acceptable molecule (protein or enzyme) to conjugate therewith and which includes in its repertoire of reaction substrates a group which is suitable as a cap as hereinbefore defined. Accordingly selection of carbohydrate is dependent on lectin recognition for the desired target cell type and selection of molecule for glycoconjugate is dependent on reaction and release of the capping moiety of
- 30 the desired drug which it is desired to deliver. Conveniently the cap may

comprise the corresponding carbohydrate known to be hydrolysed by a chosen enzyme.

A glycoconjugate as hereinbefore defined is selectively glycosylated to
5 comprise any desired carbohydrate recognised by a specific lectin to provide specific targeting to a desired cell type comprising the lectin.

The carbohydrate moiety is selected from specific oligosaccharides to be specific to different lectins, and thereby to various cell types, as hereinbefore
10 defined.

Cell-oligosaccharide combinations may be selected from for example:

Hepatocytes – galactose specific lectin^{xi}

Macrophages – mannose specific lectin^{xii}

Macrophages – mannose and mannose-6-phosphate specific lectin^{xiii}


15 Monocytes – mannose-6-phosphate lectin^{xiv}

Glycosyl groups may be linked directly or via a linker moiety, or a glycosylating precursor may comprise a linker moiety in addition to the carbohydrate moiety.

20


A linker moiety may be any suitable group which is useful in glycosylation, and is preferably selected from the following groups in which - (c) – indicates the linkage to the carbohydrate, (c)- indicates a carbohydrate moiety, - (e) – indicates the link to an atom or group X in a nucleophilic group in the molecule
25 to be glycosylated, for example each X is independently selected from NH, S or O in a nucleophilic group in an enzyme, and - (e) indicates the molecule to be glycosylated, for example an enzyme; each Y independently is selected from NH, S or O in the linker and each Z is independently selected from NH, S, CH₂ or O in a carbohydrate; and each n, a, b, c, d, e independently is selected from 1
30 to 10 or any subrange thereof for example 1 to 5 or 1 to 3:

(a) an imino alkyl group of the general formula Ia



preferably of the general formula Ia'

5 **Ia'**





wherein X is N and Z is as hereinbefore defined;

the linker of Formula Ia or Ia' is suitably obtained by the known IME reaction

as hereinbefore defined for example the corresponding imino 2-methoxy ethyl thio precursor will react with the side chain N of
10 lysine to give the linker group $-\text{SCH}_2\text{C}(\text{NH})\text{NH} - (\text{e})$;

the imino 2-methoxy ethyl thio precursor to Formula Ia or Formula Ia' is

suitably obtained by the known methoxide transformation of the
corresponding cyano thioamide, which is obtained (Ia) by known
15 means or (Ia') by the novel reaction Scheme Ia':



wherein $\text{SC}(\text{O})(\text{CH}_2)_3$ is the cyclic gamma-thiobutyrolactone and L is a
20 leaving group;


(b) a direct link of formula Ib



Wherein each of X and Z are S;

25 the group Ib is suitably obtained by known means via the 5-nitro pyridine - 2 - sulfenyl route or the methane thio sulfonate route as hereinbefore described


(c) a group of the formula Ic



wherein Z is N and X is S;

the group Ic is suitably obtained by known means via the N-acetylglucosamine
 5 route as hereinbefore described

(d) a group of formula Id



Wherein Z is CH₂, X is NH and $-C(C(O))=C(C(O))-$ is the 4-membered
 10 cyclic squarate;


the group Id is suitably obtained by known means via the squarate route as
 hereinbefore described.

Preferably the carbohydrate moiety is present in suitable amount in the range 1
 15 to 400 sugars, for example 1 to 20 sugars per site, and in 1 to 20 sites per
 glycoconjugate. Glycosylation may be in the amount 1 to 100 % of possible
 sites for a given conjugate molecule, for example 1 to 45% or 1 to 60%
 possible sites for a given enzyme molecule.


20 The carbohydrate moiety of the glycoconjugate may be any mono, di or
 polysaccharide, which may be linear or branched, and may comprise additional
 functional groups and comprise one or a combination of the known saccharide
 subunits selected from, for example, the classes of mannose, galactose, glucose,
 fucose, N-acetylglucosamine, rhamnose, saccharides and glycoconjugates
 25 thereof, such as L-rhamnose (1-OH, 2-OH, 3-OH, 4-OH, 5-Me), L-
 deoxyrhamnojirimycin (1--, 2-OH, 3-OH, 4-OH, 5-Me) and other known
 members of the saccharide classes.

Preferably the glycosyl unit and linker in combination provides a single or
 30 plural binding sites for targeting lectin, ie comprises a mono, di, poly or

dendrimeric glycosyl group. As lectin is itself a ligand it favours binding of multidentate ligands, preferably the glycosyl unit and linker comprises a divalent dendrimeric system of general formula II



wherein \sim indicates a hydrocarbyl moiety, preferably of general formula II'



wherein the linkage (c)- and -(e) is via respectively group Z or X and is selected from O, S, CH₂ or NH as hereinbefore defined, n is as hereinbefore defined, the sum of v and v' and of v and v'' independently equal the valence of N, wherein v is 0 or 1 and v' and v'' are independently 1 or 2 representing mono or polyvalent, eg di, tri or tetravalent glycan constructed from repeating branching subunits, hexa or octavalent glycan may be constructed from repeating branching subunits in corresponding manner.

The enzyme may be selected from a range of enzymes of the glycosidase, hydrolase or lyase classes, allowing a wide spectrum of prodrugs to be investigated. Enzymes are commercially available (Sigma) or may be obtained by known means, suitably from culture or the like. Suitably the enzyme is selected from any non-mammalian enzymes having no mammalian equivalent nor being a variant of a mammalian equivalent whereby the enzyme introduces a novel catalytic activity to the organism, this activity being the activity required for drug release from prodrug thereby ensuring that the system will not target any undesired locations.

Enzymes with mammalian equivalent or mammalian enzymes may be considered, with suitable modification or inhibition of the natural mammalian function.

5

Non-mammalian enzymes include the rhamnopyranosidases, beta-lactamases, penicillin V amidases; enzymes with mammalian equivalent include beta-glucuronidases; mammalian enzymes include alpha-galactosidases and alkaline phosphatases.

10

Preferably an enzyme comprises an enzyme of the class of rhamnopyranosidases since this is not found naturally in mammals, more preferably α -L-rhamnopyranosidases, most preferably comprises naringinase, alpha-L-rhamnosidase, hesperidinase or an analogue or amino-terminal sequence thereof.

15

More preferably the enzyme comprises naringinase, an analogue or amino-terminal sequence thereof, for example selected from wild type naringinase (N-WT), deglycosylated naringinase (N-DG) and otherwise functionalised naringinase (N-F) to confer properties of heat stability, activity, selectivity, to ease in formulation by solubility, solvent resistance, dispersion, to enhance taste, odour and the like; or comprises other enzymes such as lactamases, proteases, glycosidases, nitrilases, esterases, lipases, amidases, aldolases, hydrolases, lyases and the like.

25

Different cultures of enzyme may give different prodrug release specificity, for example enzymes may be commercially available (Sigma) or prepared by known means for example by fermenting in *Penicillium* sp. (deposited as DSM 6825, DSM 6826 at the Deutschen Sammlung von Mikroorganismen und Zellkulturen GmbH), separating off the biomass from the culture broth and

30

concentrating the culture supernatant, as disclosed in US 5,468,625. This enzyme has been isolated and has sequence including the active N-terminal sequence

Naringinase: (96000D) A S V P X G E X I L A P S S I E L I P T

5 Alpha-L-rhamnosidase 6826, peptide I (96000D)

D-T-N-D-Q-T-S-A-K-V-D-R-G-T-F-D-D-P-A-


And Alpha-L-rhamnosidase 6826, peptide II (93500D)

F-F-G-S-X1 (cysteine?)-Q-S-L-Y-L-K-L-V-L-K-F-G-T-L-B-D (X2?)A

10 Alpha-L-rhamnosidases (EC number 3.2.1.40) are found in a number of organisms sometimes with slightly different activities and hydrolyse the terminal non-reducing alpha-L-rhamnose residues in alpha-L-rhamnosides.

A separate study^{xv} has isolated an α -L-rhamnopyranosidase from *Aspergillus aculeatus* that can hydrolyse rhamnose from the non-reducing end of the
15 rhamnogalacturonan fragments of pectin. Nevertheless studies have shown that of the different methyl rhamnopyranosides, alpha-L-rhamnopyranosidase is specific to methyl alpha-L-rhamnopyranoside.

Preferably the enzyme is also selected according to its ability to both synthesise
20 and hydrolyse the glycosyl linkage of a desired drug. For example a β -galactosidase from *Bacillus circulans* has been shown to catalyse the formation (and therefore may be expected to catalyse its hydrolysis) of ethyl 1-thio-(β -D-galactopyranosyl)-O- β -D-glycopyranosyl disaccharides,^{xvi} employing a range of 1-thio- β -D-glycopyranosides as glycosyl acceptors and p-nitrophenyl β -D-
25 galactopyranoside as glycosyl donor (Representation 1). Yields in the range 10-60% are commonly accepted with glycosidase transformations, as was found with this example. In the same way rhamnosidases can be used to make and break rhamnoside bonds.



Representation 1: Enzymatic disaccharide synthesis

The delivery moiety of the prodrug may be selected in combination with a
 5 desired enzyme and a desired drug to deliver many appropriate drug moieties
 to the chosen site, such that the prodrug cannot be more readily cleaved to
 form the active parent drug by any other enzyme.

Preferred delivery moieties (caps) for the prodrug are selected from
 10 carbohydrate for example rhamnopyranose or variants thereof that may
 incorporate rhamnopyranose and a linker that will spontaneously, chemically
 or enzymatically fragment to release the drug, and other non-carbohydrate type
 caps that are degraded by the enzyme of choice.

15 In a further aspect of the invention there is provided a class of novel
 glycosylated conjugates of natural or synthetic rhamnopyranosidase enzymes,
 preferably glycosylated with one or more groups selected from one or a
 combination of the known saccharide subunits, for example the groups of
 mannose, galactose glucose, fucose, N-acetylglucosamine, rhamnose,
 20 saccharides and glycoconjugates thereof as hereinbefore defined as a simple
 monomeric glycosyl conjugate or as a complex di, poly or dendrimeric
 glycosyl conjugate having a suitable di, poly or dendrimeric scaffold moiety

such as a di, poly or dendrivalent atom or group, and a method for the preparation thereof.

Novel enzyme conjugates include

5

N-WT \Rightarrow GalIME

Wild type naringinase modified by IME-thiogalactoside reagent

N-WT \Rightarrow ManIME

Wild type naringinase modified by IME-thiomannoside reagent

10

N-WT \Rightarrow dendriGalIME

Wild type naringinase modified by IME-dendrithiogalactoside reagent

N-DG \Rightarrow ManIME

Deglycosylated naringinase, reglycosylated using IME-thiomannoside reagent

N-WT \Rightarrow GlyIME

15

Wild type naringinase modified by IME-thioglycoside reagent

N-WT \Rightarrow dendriGlyIME

Wild type naringinase modified by IME-dendrithioglycoside reagent

N-DG \Rightarrow GlyIME

Deglycosylated naringinase, reglycosylated using IME-thioglycoside reagent

20

N-DG \Rightarrow dendriGlyIME

Deglycosylated naringinase reglycosylated using IME-dendrithioglycoside reagent


The conjugates may be prepared by known chemical or biological techniques.

25

Preferably chemical glycosylation is by reductive amination or IME-thioglycosidation, allowing the attachment of mannose, galactose and other glyco-residues as hereinbefore defined to the surface of the enzyme structure by known means. Biological techniques include enzyme synthesis, and enzyme mutagenesis, inhibiting or overexpressing an enzyme to prevent or promote a particular linkage type may be envisaged.


30

In a further aspect of the invention there is provided a novel method for the synthesis of glycosylated enzyme conjugates, comprising in a first stage deglycosylation of the naturally occurring (WT) or synthetic enzyme according to the scheme:



wherein the reagent is suitably a competing enzyme, such as Endo-H and the like

10 followed in a second stage by protein glycosylation



with carbohydrates and linkers of formula I (Ia-I d) as hereinbefore defined using known techniques as hereinbefore defined.

15

Preferably, because it is thought that naringinase is already glycosylated, the method comprises a process of deglycosylation and reglycosylation, with the aim of allowing greater selectivity of enzyme delivery to sites of interest in the body, for example producing deglycosylated naringinase reglycosylated with linker I such as IME dendrithiogalactoside.

20


Specifically by removal of any competing glycosyl units which may have the undesirable effect of directing the enzyme to a distinct lectin specific to the competing unit, or by removal of existing similar glycosyl units in order to control the ratio of glycosyl units for controlled binding affinity, or by removal of more sterically hindered glycosyl units to improve the access and lectin binding affinity at the desired target.

25

Deglycosylation is by known methods for example N-WT \Rightarrow N-DG (or N-DG) Wild type naringinase is obtained by deglycosylation using the enzyme Endo-H.

- 5 Glycosylation may be by any known means, such as chemical modification via the linkers Ia – Id as hereinbefore defined (reductive amination ^{vii}, the IME route ^{viii}, N-acetyl route, 5-nitropyridine-2-sulphenyl route ^{xii}, cysteine specific methanethiosulphonate route ^{xi}, phenylisothiocyanate modification of lysine ^{ix}, lysine specific diethyl squarate linking ^x and the like, as illustrated in Table X),
 10 glycopeptide assembly, biological techniques, by gene expression or enzyme inhibition, or enzyme synthesis.


Preferably glycosylation is by the IME route from cyano alkyl heteroamide III as a single stage process



- wherein Y is S; and R is a hydrocarbonyl group containing heteroatoms selected from a carbohydrate having an amine group, and optionally a linker as
 20 hereinbefore defined for Ia or Ia'; for example using a modified precursor of formula Ia' according to Scheme Ia' as hereinbefore defined.

- In the case that the enzyme is not suited for any of the above techniques it may be modified by known means to introduce the appropriate initiating group, for
 25 example a modified naringinase enzyme may comprise synthetically introduced cysteine residues, which will allow the use of methane thiosulfonate reagents for glycosylation.

There is provided a class of deglycosylated enzymes of Formula IV



obtained as hereinbefore defined, wherein E is preferably a non-mammalian enzyme with no mammalian equivalent selected from the rhamnopyranosidases, beta-lactamases, penicillin V amidases; or is an enzyme with mammalian equivalent selected from beta-glucuronidases; or is a
5 mammalian enzyme selected from alpha-galactosidases and alkaline phosphatases.


There is also provided a class of novel lectin-directed glycosyl IME precursors of Formula III or IIIa as hereinbefore defined, preferably glycodendrimers
10 wherein v' is 2 and v'' is 1 or 2 whereby v is 1 or 0, for conjugation with the enzyme and a novel synthesis thereof.

The kit and method may be used for delivery of any desired known or novel prodrugs for example to inhibit an enzyme's activity, preventing the production
15 of unwanted metabolites at a particular site; to influence, ie increase or decrease, receptor response to the presence of hormones and neurotransmitters or to control the transport ability of a membrane – i.e. the range of compounds that can be transported across a particular membrane.

20 Prodrugs may be for either structurally specific or non-specific drug types, preferably specific whereby charge distribution and drug shape are complementary to generally three dimensional receptors in the body, of specific shapes and charge distributions, and will be readily accepted by the receptor, and so mimic the natural receptor/molecule interaction. EC_{50} values signify the
25 concentration required to evoke a 50% response relative to the maximum potential effect.


The drug may be selected for targeting to any desired organ and tissue types for example the liver, extrahepatic tissue or organs, the lungs, the gastrointestinal
30 or skin, where the drug is known to be metabolised.

Known prodrugs which may be delivered by the system of the invention include rhamnosides of any amine or alcohol or thiol where modification of this group reduces effects e.g., N-linked rhamnoside of methotrexate as an example of an anticancer compound, rhamnoside of vancomycin as an example of a proantibiotic, rhamnoside of doxorubicin, which has a free amino group suitable for coupling to para hydroxyphenoxy acetic acid, which is hydrolysed by a glycopeptidase conjugate, Verbascoside which is a phenylethyl glycoside with antiviral, antibacterial and antitumour properties, also an inhibitor of aldose reductase and protein kinase C, commercially available by a twenty step synthesis




Representation 2: Verbascoside

; and phenolic glycoside^{xvii} 1-(α -L-rhamnosyl(1-6)- β -D-glucopyranosyloxy)-3,4,5-trimethoxybenzene (Representation 3) obtained from methanolic bark extract of *Ravensura anisata* Danguy (Lauraceae) from Madagascar which may be synthesised according to the invention by a simple enzyme synthesis using limited protection/deprotection and an α -rhamnopyranosidase.



Representation 3: Rhamnose-containing phenolic glycoside

and 1-O-galloyl- α -L-rhamnose (Representation 4), a natural antibiotic isolated
5 from the leaves of *Acer rubrum* L., an eastern Canadian red maple.^{xviii}



Representation 4

Drugs may include but not be limited to compounds acting to treat the
10 following:

Infections such as antiviral drugs, antibacterial drugs, antifungal drugs,
antiprotozoal drugs, anthelmintics;

Cardiovascular system such as positive inotropic drugs, diuretics, anti-
arrhythmic drugs, beta-adrenoceptor blocking drugs, calcium channel blockers,
15 sympathomimetics, anticoagulants, antiplatelet drugs, fibrinolytic drugs, lipid-
lowering drugs;

Gastro-intestinal system agents such as antacids, antispasmodics, ulcer-healing, drugs, anti-diarrhoeal drugs, laxatives, central nervous system, hypnotics and anxiolytics, antipsychotics, antidepressants, central nervous system stimulants, appetite suppressants, drugs used to treat nausea and vomiting, analgesics, antiepileptics, drugs used in parkinsonism, drugs used in substance dependence;

Malignant disease and immunosuppression agents such as cytotoxic drugs, immune response modulators, sex hormones and antagonists of malignant diseases;

10 Respiratory system agents such as bronchodilators, corticosteroids, cromoglycate and related therapy, antihistamines, respiratory stimulants, pulmonary surfactants, systemic nasal decongestants;

Musculoskeletal and joint diseases agents such as drugs used in rheumatic diseases, drugs used in neuromuscular disorders; and

15 Immunological products and vaccines.

Prodrugs which may be delivered according to the invention include conjugates of a desired drug and a natural or synthetic carbohydrate or other activity suppressing cap as hereinbefore defined, specifically to a class of prodrug conjugates incorporating a natural or synthetic glycosyl group selected from an α -rhamnopyranosidic group, galactoside group, peptide group, glycoside group and other carbohydrate residues as hereinbefore defined and the like; or a natural or synthetic non glycosyl group selected from ester groups and the like; and other non-natural caps which may be processed by a glycoconjugate of the invention in the same way to release drug.

The prodrug is commercially available or is suitably prepared by any known means or in novel manner by enzyme synthesis preferably using the enzyme corresponding to the glycoconjugate. The use of enzymes to create the cap-to-drug linkage indicates by the principle of microreversibility that the same enzyme will also catalyse its cleavage under appropriate conditions.

It is an advantage that rhamnose type "caps" have been found to be stable to protease activity, by incubation in bacteria after which they have been found to be intact and the activation mechanism to release drug to be intact. In the case that the prodrug is capable of being hydrolysed by a native enzyme, it may be possible to coadminister with a suitable inhibitor, specific to that enzyme, to ensure prodrug delivery is targetted.

In a further aspect, the invention provides a prodrug of a class comprising prodrugs having carbohydrate cap as hereinbefore defined selected from prodrug conjugates incorporating a natural or synthetic glycosyl group selected from an α -rhamnopyranosidic group, galactoside group, peptide group, glycoside group and other carbohydrate residues as hereinbefore defined and the like, wherein the prodrugs have been obtained by enzyme synthesis with use of the corresponding non-mammalian occurring natural or synthetic enzyme selected from a rhamnopyranosidase enzyme such as naringinase, galactosidase, peptidase, glycosidase and the like or other enzyme as hereinbefore defined; or incorporating a natural or synthetic non glycosyl group selected from ester groups and the like wherein the prodrugs have been obtained by enzyme synthesis with use of a non-mammalian occurring natural or synthetic enzyme such as a peptidase.

Enzyme synthesis of prodrug is suitably by known means by contacting the selected drug in reactive form, ie as an acceptor of the selected cap, the selected cap donor and any other reagents in the presence of a suitable enzyme.

Preferably enzyme synthesis takes place in organic cosolvent to reduce competition between the glycosyl acceptor (drug) and water as nucleophile, by reducing the number of available water molecules.

5 Enzyme kinetic studies illustrate the effectiveness of an enzyme to carry out a particular transformation. Preferably the prodrug comprises a tracer group such as a chromophoric group, a radioactive moiety or the like whereby uptake of glycosyl groups in the drug and delivery of the drug in vivo may be monitored by depletion or production of that group. Tracer group are selected from those
10 which will spontaneously fragment eg carbonates, carbamates, para-alkoxybenzyl under suitable conditions of pH, catalysis or that afford some form of response to chemical or biological stimulus that can be monitored or exploited in an environment specific release. A tracer group may be traceable in its intact or fragmented form. A chromophoric group or fragment may be
15 traced by UV/visible spectrophotometry or a radioactive group such as I ¹³⁵ by scintillation counting as known in the art and the like.

There is further provided the novel enzyme synthesis of alpha-rhamnose prodrugs as hereinbefore defined.

20

In enzyme synthesised glycosylation the peptide sequence affects glycosylation by making potential glycosyl acceptors unavailable, by folding into a pocket or side-chain hindrance. The type and amount of enzyme also affects glycosidation patterns. Accordingly there is an advantage to employing the
25 corresponding technique both to make and to break the prodrug bond.

Although α -L-rhamnosidase enzymes are known from a number of industrial and research applications to hydrolyse terminal non-reducing α -L-rhamnose residues in α -L-rhamnosides.^{xix} (It should be noted that α -L-rhamnopyranosidases (E.C. number 3.2.1.40) are found in a number of
30

different organisms, sometimes with slightly different activities), they have not previously been used to glycosylate prodrugs.

There is further provided a method of treatment comprising administering a
5 lectin-directed glycoconjugate and a corresponding prodrug as hereinbefore defined; the method allows reduced side effects and improved specificity allowing reduced dosage quantity.

Suitably the conjugate and prodrug are adapted for administration by any
10 appropriate means such as oral, parenteral, inhalation, topical, intravenous, rectal etc. The conjugate is adapted for administration and predetermined circulation period, for example of the order of up to 30 minutes such as 10 minutes, allows it to circulate and target the desired cells, by lectin recognition, and to clear the system in all other locations. The prodrug is adapted to be
15 administered separately and circulates until it locates the enzyme. At this point prodrug cleavage occurs with release of drug. Preferably the enzyme conjugate remains in place for a plurality of prodrug doses.

There is further provided a dosing regime comprising a period for
20 glycoconjugate dosing and one or more sub periods for prodrug dosing. The dosing regime may be reliant on high affinity of conjugate for lectin, and an abundance of prodrug cleavage sites, in the case that the drug is released by association of the "cap" with the enzyme, or alternatively the "cap" is released as a free entity and is cleared from the system independently of the enzyme.

25

There is also provided a novel composition comprising a glycosylated rhamnopyranosidase together with pharmaceutically acceptable excipients, carriers and the like suitable for mammalian, preferably human administration.

There is also provided a novel composition comprising a prodrug obtained by enzyme synthesis to introduce a cap as hereinbefore defined together with pharmaceutically acceptable excipients, carriers and the like suitable for mammalian, preferably human administration.

5 There is also provided the novel medical use of a glycosylated rhamnopyranosidase in the treatment of a mammal, preferably in the treatment of a human.

10 The inventor has devised a novel method for obtaining pure rhamnopyranosidase enzyme, in particular pure naringinase enzyme. The purification method comprises dialysing a crude preparation of enzyme, subjecting the product of the dialysis to size exclusion chromatography and subjecting the product of the size exclusion chromatography to ion-exchange
15 chromatography. This method allows 500mg crude naringinase to yield 30mg pure rhamnosidase activity.

The pure rhamnopyranosidase enzyme has rhamnosidase activity and is not generally contaminated by detectable glucosidase activity. In a composition
20 containing pure rhamnopyranosidase enzyme, the enzyme may constitute e.g. more than 80%, more than 90%, more than 95%, more than 98% or more than 99% of the protein in the composition. A composition containing the enzyme may give a single band in 10% SDS-PAGE. The pure enzyme may be wild-type, deglycosylated or modified with a carbohydrate so as to produce a lectin-
25 directed glycoconjugate of the invention.

Examples

The invention is now illustrated in non-limiting manner with reference to the
30 following examples.

Melting points were recorded on Gallenkamp melting point apparatus. Proton nuclear magnetic resonance (NMR) spectra were recorded, unless otherwise stated, at 200MHz on a Varian Unity 200 spectrometer. All chemical shifts are
5 quoted on the δ scale using residual solvent as standard. Mass spectra were recorded by the Durham University mass spectrometry using electrospray, unless otherwise stated. Microanalysis was performed by the microanalysis service at Durham University. Thin layer chromatography was carried out on aluminium sheets coated with silica gel 60 F₂₅₄. Plates were developed using an
10 ammonium molybdate dip, or a methanol/sulfuric acid dip.

Brief description of the drawings

Figure 1: 10% SDS-PAGE of wild-type naringinase (N-WT) subjected to
15 freezing (lane 2) or freeze-drying (lane 3). The left-hand lane contains molecular weight markers and lane 1 contains a sample of N-WT that was not subjected to any treatment (i.e. not subjected to freezing or freeze-drying).

Figure 2: comparison of absorbance at 280 nm with rhamnosidase activity and
20 glucosidase activity in fractions of N-WT from a BioGel™ P-2 purification column.

Figure 3: comparison of absorbance at 280 nm with rhamnosidase activity and
25 glucosidase activity in fractions of N-WT from a BioGel™ P-100 purification column.

Figure 4: 10% SDS-PAGE of fractions of N-WT from a BioGel™ P-100 purification column. The left lane contains molecular weight markers.

Figure 5: comparison of absorbance at 280 nm with rhamnosidase activity and glucosidase activity in fractions of N-WT from a BioGel™ P-100 purification column.

5. Figure 6: comparison of absorbance at 280 nm with rhamnosidase activity and glucosidase activity in fractions of N-WT from a Millipore Vantage-L™ purification column.

- Figure 7: comparison of absorbance at 280 nm with rhamnosidase activity and
10 glucosidase activity in fractions of N-WT from a DEAE Sepharose™ purification column.

- Figure 8: comparison of absorbance at 280 nm with rhamnosidase activity and
15 glucosidase activity in fractions of N-WT from a Sephadex G25™ purification column.

Figure 9: 10% SDS-PAGE of various forms of N-WT.

- Lane 1 - molecular weight markers
20 Lane 2 - wild-type naringinase (N-WT)
Lane 3 - N-WT-GalIME
Lane 4 - N-WT-ManIME
Lane 5 - deglycosylated naringinase (N-DG)
Lane 6 - N-DG-GalIME
25 Lane 7 - empty
Lane 8 - N-WT
Lane 9 - N-WT-dGalIME

Figure 10: enzyme activity of N-WT at varying pH.

Figure 11: enzyme activity of N-DG at varying pH.

Figure 12: activities of wild-type and variously modified forms of naringinase.

- 5 Figure 13: radio-imaging of rabbits treated with radio-labeled wild-type naringinase modified with GalIME (N-WT-GalIME), either alone (top panels) or with the blocker asialofetuin (AF) (bottom panels).

- 10 Figure 14: liver retention of N-WT-GalIME over 120 min, either alone or with the blocker asialofetuin (AF).

Figure 15: liver retention of N-WT-dGalIME over 120 min, either alone or with the blocker asialofetuin (AF).

- 15 Figure 16: extinction coefficient of *p*-nitrophenol (pNP) in tritosome assay conditions (blanked to zero).


Figure 17: tritosomal stability of N-WT.

- 20 Figure 18: panel (a) shows a section from liver of N-DG-dGalIME dosed animal under phase imaging conditions and panel (b) shows the same section in the same orientation under fluorescence imaging conditions with a substrate that generates a fluorescent product.

A Preparation of Glycosylation precursors:

Example A1 - Novel Synthesis of cyano precursor to galactose dendrimer
IME,

The synthesis was first conducted to prepare N-Benzyl-4-cyanomethylsulfanyl-butamide




Benzylamine (0.55ml, 5.0mmol), γ -thiobutyrolactone (0.87ml, 10.0mmol) and chloroacetonitrile (1.58ml, 25mmol) were added to an aqueous solution of sodium hydrogen carbonate (30ml, 0.5M) and methanol (25ml) in a round bottom flask fitted with reflux condenser, magnetic stirrer bar and inert atmosphere. The mixture was heated overnight at 50°C.

The methanol was removed in vacuo, and the resultant aqueous layer extracted with chloroform (3 \times 60ml). The organic layers were combined and washed with hydrochloric acid (3 \times 60ml, 1M) then dried over magnesium sulfate. This solution was filtered, and all solution removed in vacuo.

The product oil was purified by flash chromatography (3:1 EtOAc:Hexane + 1% Et₃N).

Yield = 0.57g, 46%. $^1\text{H-NMR}$ (250MHz CDCl_3) δ 2.04 (quin, 2H, H^{10}), 2.36, 2.80 (2xt, $2 \times 2\text{H}$, H^9 & H^{10}), 3.28 (s, 2H, H^{12}), 4.43 (d, 2H, H^7), 5.85 (s, 1H, NH), 7.26-7.31 (5xs, 5H, Ph)

5 Synthesis of cyano precursor glycodendrimer-IME reagent




- Bis{N-[2-(1-thio-β-D-galactopyranosyl)ethanoyl]aminoethyl}amine (98.9mg, 0.16mmol), γ-thiobutyrolactone (0.14ml, 1.6mmol) and chloroacetonitrile (0.20ml, 3.2mmol) were added to an aqueous solution of sodium hydrogen carbonate (1ml, 0.5M) and methanol (1ml) in a round bottom flask fitted with reflux condenser, magnetic stirrer bar and inert atmosphere. The mixture was heated for 24 hours at 50°C.
- 15 The mixture was neutralized with 2M HCl, concentrated in vacuo and purified by flash chromatography (CHCl_3 : MeOH : H_2O : Et_3N 60:35:7:1) to yield a product, which was taken to dryness in vacuo. The product was then loaded onto Dowex 50W2-200 (H^+) in water: methanol 1:1 and eluted with 10% NH_3 solution. The product dried by freeze-drying.

Yield = 54.7mg, 45%. ^1H NMR (300MHz, CD_3OD) \sim 1.25 (t, 4H, CH_2CN), 2.18 (q, 2H), 2.5 (t, 2H), 2.7 (t, 4H), 2.9 (dd, 2H), 3.35 (m, 24H), 4.47 (d, 2H, anomeric H). Mass confirmed by ES-MS.

5

Ex A 2 Preparation of 1,2,3,4,6-penta-O-acetyl β -D-mannopyranoside:




Sodium acetate (10g, 121.9mmol) was suspended in acetic anhydride (70ml),
 10 heated until gently refluxing and then removed from the heat. Small portions of
 D-mannose (total 10g, 55.49mmol) were added at a rate that maintained
 reaction. A heat gun was used to maintain reaction temperature where
 necessary. After the reaction had subsided, as detected by a lack of bubbling,
 the orange coloured mixture was returned to the heat and refluxed for 1 hour.
 15 The mixture was allowed to cool and was then poured into ice water (200ml)
 and left to stand, with occasional stirring, for 3 hours. This yielded a dark
 brown mixture with little separation between organic and aqueous layers.
 Extraction by ethyl acetate (5 \times 150ml) followed by evaporation in vacuo
 yielded a dark brown syrup. Purification by flash column chromatography (3:1,
 20 ethyl acetate:hexane) yielded an orange oil, (8).

Yield: 19.83g, 91.6%. Elemental analysis: Theoretical: C 49.2%; H 5.68%; N
 0.0%; Actual: C 49.49%; H 6.09%; N 0.00%. ^1H NMR (200MHz, CDCl_3 , α : β
 10:1) δ 1.72, 1.75, 1.78, 1.79, 1.80, 1.81, 1.90, 1.92 (s \times 8, 3H \times 10, Ac \times 10, 2
 25 anomers), 3.82 (dd, 1H, J=5, J=12), 4.00 (dd, 1H, J=5, J=12) 5.0 (m, 2H), 5.79

(d, 1H, J=2, H-1, α), 5.92 (d, 1H, H-1, β). $[\alpha]_D^{23.3} = +37.895$ (CHCl_3 , $c = 2.66$). $\text{Mpt}^\circ = 93.2 - 95.2^\circ\text{C}$.

Ex A3 Preparation of 1,2,3,4,6-penta-O-acetyl β -D-galactopyranoside:




Sodium acetate (10g, 121.9mmol) was suspended in acetic anhydride (70ml), heated until gently refluxing and then removed from the heat. Small portions of D-galactose (total 10g, 55.49mmol) were added at a rate that maintained reaction. A heat gun was used to maintain reaction temperature where necessary. After the reaction had subsided, as detected by a lack of bubbling, the orange coloured mixture was returned to the heat and refluxed for 1 hour.

The mixture was allowed to cool and was then poured into ice water (200ml) and left to stand, with occasional stirring, for 3 hours. This yielded a dark brown mixture with little separation between organic and aqueous layers.

Extraction by ethyl acetate (5x150ml) followed by evaporation in vacuo yielded a dark brown syrup. Purification by flash column chromatography (3:1 ethyl acetate:hexane) yielded an orange oil, (6).

Yield 19.27g, 89.0%. Elemental analysis: Theoretical: C 49.2%; H 5.68%; N 0.0%; Actual: C 49.18%; H 5.71%; N 0.0%. ^1H NMR (200MHz, CDCl_3) δ 2.00 2.03 2.05 2.13 2.17 (s \times 5, 3H \times 5, Ac \times 5), 4.10 (m, 3H, H-5, H-6, H-6') 5.08 (dd, J 3Hz J 10Hz, 1H, H-2), 5.36 (m, 2H, H-3, H-4), 5.70 (d, J=8, 1H, H-1).

Ex A4 Preparation of 2,3,4,6-tetra-O-acetyl- α -D-mannopyranosyl bromide:


5

1,2,3,4,6-O-pentaacetyl D-mannopyranose, (3.69g, 9.45mmol) was dissolved in dry dichloromethane (130ml) and stirred in a 250ml round bottom flask at 0°C under a nitrogen atmosphere. Hydrogen bromide (20ml, 30% in acetic acid) was added slowly, and the mixture stirred at 0°C for 15 minutes before warming to room temperature. The reaction was followed by thin layer chromatography, using 1:1 ethyl acetate: hexane (R_F starting material = 0.3, product = 0.5).

After 4 hours the green/brown mixture was poured over ice and a colour change to white was observed. This solution was washed with a saturated solution of sodium hydrogen carbonate (3×120ml) and then with water (2×120ml). The organic layer was dried over magnesium sulfate, filtered, and taken to dryness in vacuo, yielding a clear, viscous oil (9).

Yield 2.38g, 61.3%. Elemental analysis: Theoretical: C 40.90%; H 4.66%; N 0.00%; Actual: C 40.31%; H 4.59%; N 0.00%. ^1H NMR (250MHz, CDCl_3) δ 1.95 2.01 2.04 2.11 (s×4, 3H×4, Ac×4), 4.07 (dt, H×1, H-5), 4.15 (m, H×1, H-4), 4.25 (dd, H×1, H-3), 5.31 (m, H×2, H-6 H'-6), 5.65 (dd, H×1, H-2), 6.23 (d, H×1, H-1). ESMS Required peak 433/435, observed peak 433/435. $[\alpha]_D^{23.3} = +123.757$ (CHCl_3 , $c = 1.81$).

Synthesis of 2-Imino-2-methoxyethyl 1-Thioglycosides:


Ex A5 Synthesis of 2-S-(2,3,4,6-tetra-O-acetyl- β -D-galactopyranosyl)-5 2-thiopseudourea hydrobromide (TPU derivative of galactose):

10

11

Acetobromo- α -D-galactose (16.448g, 40mmol) and thiourea (3.958g, 52mmol) were suspended in dry acetone (15ml) in a 250ml round bottom flask fitted with a magnetic stirrer and reflux condenser, under a nitrogen atmosphere. The mixture was refluxed for 2 hours and the reaction followed by tlc, reduced in volume (30ml) in vacuo and chilled for 3 hours. The resulting white crystals (11) were filtered, washed with cold acetone and dried.

Yield: 14.24g, 73.1%. Elemental Analysis: Theoretical: C 36.97%; H 4.76%; N 5.75% Actual: C 38.79%; H 5.23%; N 5.28%. ^1H NMR (CDCl_3 , 199.99Hz): δ = 1.982-2.186 (s, 4 OAc), 4.147-4.179 (s, 2H^6), 4.46 (d, H^1), 5.2 (dd, H^2), 5.379 (td, H^5), 5.486 (dd, H^3), 5.529 (dd, H^4), 8.294 (s, NH_2), 9.445 (s, NH_2). ^{13}C NMR (CDCl_3 , 62.90MHz): δ = 20.4-20.8 (4 \times Acetyl-Me), 30.9 (imidate carbon), 61.2-82.0 (6 \times ring carbons), 169.0-170.8 (4 \times Acetyl carbonyl). $[\alpha]_{\text{D}}^{21.6}$ = + 0.6 (CHCl_3 , c = 1.0). Mpt $^\circ$ = 174.7 – 176.5.


Ex A6 Synthesis of Cyanomethyl Per-O-acetyl-1-thiogalactopyranoside:

11

12


- 11 (3.7g, 7.6mmol) was stirred with dry acetone (20ml) and water (20ml) was added. Sodium bisulfite (2.0g, 38mmol), potassium carbonate (1.6g, 11.5mmol) and chloroacetonitrile (2.5ml, 40mmol) were then added in order, and the mixture stirred at room temperature for 3 hours. This mixture was then added to ice water (40ml) and stirred for 2.5 hours at 4°C. Some acetone (20ml) was removed in vacuo and the resulting mixture chilled overnight in a refrigerator.
- The red gum product was extracted with chloroform (2×40ml) treated with decolourising charcoal, and filtered through a Celite column and the extract washed with sodium chloride solution (3×40ml, 1M), and the resulting organic layer was dried over anhydrous sodium sulfate. The chloroform solution was then evaporated to dryness in vacuo and the product gum recrystallized from hot ethanol, yielding a white crystalline solid.

Yield: 1.545g, 50.4%. Elemental Analysis: Theoretical: C 47.65%; H 5.25%; N 3.47% Actual: C 47.61%; H 5.27%; N 3.46%. ¹H NMR (CDCl₃, 199.99Hz): δ = 1.993-2.169 (s, 4 OAc), 3.492 (s, 2H⁷), 4.0 (dd, H²), 4.135-4.162 (dd, 2H⁶), 4.6985 (d, H¹), 5.1 (dd, H³), 5.252 (td, H⁵), 5.466 (dd, H⁴). ¹³C NMR (CDCl₃, 62.90MHz): δ = 14.4 (C-7), 20.5-20.7 (4×Acetyl-Me), 61.3-82.2 (6×ring carbons), 115.7 (cyano-carbon), 169.8-170.3 (4×Acetyl carbonyl). [α]_D^{21.7} = -56.96 (CHCl₃, c = 0.95). Mpt° = 93.2–95.2°C.

Ex A7 Synthesis of 2-Imino-2-methoxyethyl 1-thiogalactoside:

- 5 A solution of cyanomethyl per-O-acetyl-1-thiogalactopyranoside (0.4805g, 1.19mmol) in dry methanol (20ml) was added to a methanolic solution of sodium methoxide (0.01M, 30ml) and stirred at room temperature under a nitrogen atmosphere for 48 hours. The methanol was removed in vacuo, and protein conjugation attempted immediately.

10


Ex A8 Preparation of 2-S-(2,3,4,6-tetra-O-acetyl α -D-mannopyranosyl)-2-thiopseudourea hydrobromide:

- 15 Acetobromo- α -D-mannopyranoside (2.36g, 5.7mmol) and thiourea (0.574g, 7.54mmol) were suspended in dry acetone (25ml) in a 50ml round bottom flask fitted with a reflux condenser and magnetic stirrer. The mixture was refluxed for 3 hours, 20% of the solvent was removed in vacuo, and then chilled in an ice bath for 2 hours. As no precipitation occurred, the solution was chilled in a freezer overnight. Still no precipitation was observed, so all solvent was removed in vacuo yielding a pale yellow semi-crystalline gum. Recrystallisation

from hot ethyl acetate resulted in precipitation of product. After filtration and drying in vacuo, the reaction yielded a white powder (14).

Yield: 0.393g, 14.16%. Elemental Analysis: Theoretical: C 36.97%; H 4.76%; N 5.75% Actual: C 36.85%; H 4.72%; N 5.48%. ^1H NMR (CDCl_3 , 499.78Hz): δ 2.013, 2.100 2.131 2.195 (s \times 4, 3H \times 4, Ac \times 4), 4.20 (dd, H \times 1, H-3), 4.310 (dd, H \times 1, H-4), 4.385 (td, H \times 1, H-5), 5.09 (dd, H \times 1, H-2), 5.313 (t, H \times 1, H-6), 5.430 (d, H \times 1, H-1), 8.231 (s, H \times 2, -NH $_2$), 9.725 (s, H \times 2, -NH.HBr). ^{13}C NMR (CDCl_3 , 62.90MHz): δ = 20.5-20.8 (4 \times acetyl methyl), 61.8-82.4 (6 \times ring carbons), 169.2-170.4 (4 \times acetyl carbonyl).

Ex A9 Preparation of cyanomethyl per-O-acetyl-1-thiomannopyranoside:



15


2-S-(2,3,4,6-tetra-O-acetyl α -D-mannopyranosyl)-2-thiopseudourea hydrobromide (0.37g, 0.76mmol) was suspended in acetone (2ml), to which water (2ml), sodium bisulfite (0.2g, 3.8mmol), potassium carbonate (0.16g, 1.15mmol) and chloroacetonitrile (0.25ml, 4mmol) were then added, in order. This mixture was stirred at room temperature for 3 hours, then poured over ice water (15ml) and stirred at 4°C for 2 hours. A white precipitate formed, and was filtered, washed with iced water and then dried in vacuo. Recrystallisation from hot methanol yielded a white solid (15).

Yield: 84.4mg, 27.5%. Elemental Analysis: Theoretical: C 47.65%; H 5.25%; N 3.47% Actual: C 47.39%; H 5.22%; N 3.36%. ^1H NMR (CDCl_3 , 499.78Hz): δ 2.003, 2.065, 2.112, 2.189 (s \times 4, H \times 12, Ac \times 4), 3.342 (dd, H \times 2, $-\text{CH}_2-$), 4.18 (dd, H \times 1, H-2), 4.343 (m, H \times 3,), 5.20 (dd, H \times 1, H-3), 5.34 (dd, H \times 1, H-4), 5.376 (t, H \times 1,), 5.462 (d, H \times 1, H-1). ^{13}C NMR (CDCl_3 , 62.90MHz): δ = 15.8 ($-\text{S}-\text{CH}_2-\text{CN}$), 20.2-21.1 (4 \times Acetyl-Me), 62.1-82.4 (6 \times ring carbons), 115.9 (cyano-carbon), 169.8-171.0 (4 \times Acetyl carbonyl). ESMS Required peak 426, observed peak 426. $[\alpha]_{\text{D}}^{21.7} = +111.7$ (CHCl_3 , $c = 0.52$). $\text{Mpt}^\circ = 111.2 - 113.4^\circ\text{C}$.

10

B Glycosylation Reactions: preparation of glycoconjugate


Ex B1 Glycosylation of naringinase using IME-thiogalactoside:



13 (1.19mmol) was kept in its round bottom flask, a solution of naringinase (0.1070g in 20ml 0.25M sodium borate – pH8.5) was added. And the mixture was stirred under a nitrogen atmosphere for 48 hours. After this time, purification by Biogel P-2 was carried out (2 \times 60cm, 0.1M NaCl, pH4.8) 0.1M sodium chloride solution, pH 4.8, as eluant. Presence of protein was detected by spectroscopy (absorbance at 280nm) and the relevant fractions were combined and freeze dried.

Ex B2 IME-thiomannosidation of WT naringinase

1.1



One major aspect of this work to introduce specific carbohydrate moieties to the surface of naringinase, the α -rhamnopyranosidase, with the aim of being able to specifically deliver naringinase to particular cell types using lectin-carbohydrate interactions. This requires the investigation of a number of glycosylation techniques, namely reductive amination and the use of IME-thioglycosides. Both techniques rely on the presence of free amino groups within the protein structure – and that these amino groups are not hindered by the presence of large sterically prohibitive groups within the protein structure.

Naringinase was treated with IME-thiomannoside, in an attempt to modify any accessible amino groups on the surface of the protein. The cyanomethyl per-O-acetyl-1-thiomannoside (12) was treated with a methanolic solution of sodium methoxide, yielding the IME-thiomannoside (13). Once all solvent had been removed from the flask in which the IME-thiomannoside had been prepared, a solution of naringinase with sodium tetraborate buffer (pH 8.5) was added, and stirred under an inert atmosphere for two days.

BioGel P2 size exclusion chromatography (2×60cm, 0.1M NaCl, pH 4.8) was used to purify the naringinase, with aliquots tested by absorption at 280nm to detect presence of protein. Relevant fractions were combined and freeze-dried before being tested for enzyme activity. 12.5% SDS PAGE was used to determine any change in mass brought about by this method.

Ex B3 Deglycosylation of enzyme

25

Purification of Endoglycosidase H

A stock solution of Endoglycosidase H (EndoH) (1ml, 10mg/ml) was diluted to 20ml with deionised water and then dialysed using Visking tubing (12-14 kDa MWCO) against deionised water for 24 hours, with water changes at 1, 6 and

30

18 hours. The resultant solution was freeze-dried yielding a white powder. Purity was assessed by gel electrophoresis (SDS PAGE), in the gel a reduction in molecular weight of around 25-30kDa is clearly observed (the difference between bands 2 and 5).

5

Deglycosylation of N-WT (i.e. preparation of N-DG)

Two comparable methods have been tested, in an attempt to assess the effect of scale on reaction success.

10


A solution of N-WT (5ml, 10mg/ml in 10mM pH6.0 orthophosphate buffer) and a solution of EndoH (25µl, 10mg/ml solution) were combined in a sample vial fitted with a magnetic stirrer bar and heated at 37°C for 24 hours. The solution was transferred to a Spectrum DispoDialyser® (50 kDa MWCO) and dialysed against deionised water for 24 hours, with water changes at 1, 6 and 18 hours. The resultant solution was freeze-dried yielding a white powder. Purity was assessed by gel electrophoresis (SDS PAGE), see later.

15

A solution of N-WT (20ml, 10mg/ml in 10mM pH6.0 orthophosphate buffer) and a solution of EndoH (100µl, 10mg/ml solution) were combined in a round bottom flask fitted with a magnetic stirrer bar and heated at 37°C for 24 hours. The solution was transferred to Spectrum Cellulose Ester dialysis tubing (50 kDa MWCO) and dialysed against deionised water for 24 hours, with water changes at 1, 6 and 18 hours. The resultant solution was freeze-dried yielding a white powder. Purity was assessed by gel electrophoresis (SDS PAGE), see later.

20

25

Ex B 4 Preparation of N-DG→GalIME

- 5 GalIME reagent (45mg, 0.11mmol) was dissolved in dry methanol (20ml) in a 100ml round bottom flask fitted with a magnetic stirrer under an inert atmosphere. A methanolic solution of sodium methoxide (30ml, 0.01M) was added, and the mixture stirred for 36 hours at room temperature.
- 10 The contents of the flask were taken to dryness in vacuo, and a solution of N-DG (2ml, 5mg/ml in 0.25M sodium borate, pH8.5 corrected with cHCl) was added. The mixture was stirred under a nitrogen atmosphere for 36 hours. After this time, the solution was purified by Biogel P-2 column (2×60cm, 0.1M NaCl, pH4.8) with presence of protein detected by spectroscopy (absorbance at
- 15 280nm). Appropriate fractions were combined and freeze dried, resulting in a white powder. Purity was assessed by gel electrophoresis (SDS PAGE), Successful glycosylation was detected, the difference between bands 5 and 6 suggests an increase in molecular weight of around 1.5kDa, equivalent to the addition of ten carbohydrate molecules to the protein.

20

Protein purification


- All naringinase samples were desalted using Sephadex PD10 desalting columns. A maximum of 25mg protein was put on to each column, which were
- 25 pre-eluted with deionised water. SDS PAGE has been employed successfully in the determination of molecular weights of all protein samples. The appropriate fractions were combined and freeze-dried.

Gel electrophoresis

- Aqueous solutions of all naringinase samples were prepared (2mg/ml) and loaded onto 12% gels in the usual manner. The gels were run at 150V for 3 hours, removed and stained overnight, followed by destaining overnight to remove background stain and molecular weight successfully assessed for all samples, 1 BioRad SDS PAGE Protein Standard (from top: 97.4, 66, 45 (faint), 31kDa)
- 2 N-WT, 3 N-WT→GalIME, 4 N-WT→ManIME, 5 N-WT→N-DG, 6 N-DG→GalIME.

C Enzymatic Synthesis: preparation of Prodrug

- Ex C1 Enzymatic reaction between β -methyl glucopyranoside and p-nitrophenyl α -L-rhamnopyranoside:



- A solution of p-nitrophenyl α -L-rhamnopyranoside (3.5mM, 0.0050g, 1.75×10^{-5} mol) in orthophosphate buffer (5ml, pH 7.0) was stirred in a 50ml round bottom flask in a graphite bath thermostatted to 37°C. A solution of β -methyl glucopyranoside (0.0204g, 1.05×10^{-4} mol) in orthophosphate buffer (3ml, pH 7.0) was added, with naringinase (0.0147g, 5 Units) and an inert atmosphere


introduced. The reaction was followed by thin layer chromatography (1:9 methanol:ethyl acetate) and when all glycosyl donor was consumed the reaction was quenched by placing in a water bath at 100°C for 5 minutes. All water was removed by freeze-drying.

5

Ex C2 Acetylation of enzyme reaction

Dry pyridine (20ml) and acetic anhydride (10ml) were added to the crude product of MAR48, and stirred in a 50ml round bottom flask overnight.
 10 Methanol (20ml) was added, whilst the mixture was cooling in an ice bath, to quench the reaction, and then all solvents were removed in vacuo. The residue was dissolved in dichloromethane (15ml) and washed with a sodium hydrogen carbonate solution (0.05M, 3×40ml). The organic layer was dried over magnesium sulfate, filtered and all solvent removed in vacuo. This mixture was
 15 purified by flash chromatography, using a 1:1 ethyl acetate:hexane solvent system.

Ex C3 Enzymatic reaction between β -methyl galactopyranoside and p-nitrophenyl α -L-rhamnopyranoside:



20

A solution of p-nitrophenyl α -L-rhamnopyranoside (3.5mM, 0.0050g, 1.75×10^{-5} mol) in orthophosphate buffer (5ml, pH 7.0) was stirred in a 50ml round

bottom flask in a graphite bath thermostatted to 37°C. A solution of β -methyl galactopyranoside (0.0323g, 1.663×10^{-4} mol) in orthophosphate buffer (3ml, pH 7.0) was added, with naringinase (0.0147g, 5 Units) and an inert atmosphere introduced. The reaction was followed by thin layer chromatography (1:9
5 methanol:ethyl acetate) and when all glycosyl donor was consumed the reaction was quenched by placing in a water bath at 100°C for 5 minutes. All water was removed by freeze-drying.

Ex C4 Acetylation of enzyme reaction

10

Dry pyridine (20ml) and acetic anhydride (10ml) were added to the crude product of MAR50, and stirred in a 50ml round bottom flask overnight. Methanol (20ml) was added, whilst the mixture was cooling in an ice bath, to quench the reaction, and then all solvents were removed in vacuo. The residue
15 was dissolved in dichloromethane (15ml) and washed with a sodium hydrogen carbonate solution (0.05M, 3×40ml). The organic layer was dried over magnesium sulfate, filtered and all solvent removed in vacuo. This mixture was purified by flash chromatography, using a 1:1 ethyl acetate:hexane solvent system.

20

NMR Study:


Solutions of p-nitrophenyl α -L-rhamnopyranoside (3mM, 200 μ l) and β -methyl galactopyranoside (18mM, 200 μ l) in water were mixed in an NMR tube fitted
25 with a capillary insert dilled with D₂O. Suppression of the water signal in the sample was achieved by pre-irradiating the sample at the appropriate water signal frequency. An aliquot of naringinase solution (20 μ l, 1mg/ml, pH 7.0 orthophosphate buffer) was added to the NMR tube and an NMR spectrum taken every two minutes for four hours.

D Preparation of Prodrug

Synthesis of Naringinase substrate – p-nitrophenyl α -L-rhamnopyranoside:


5

The starting material p-nitrophenyl α -L-rhamnopyranoside (18) was synthesised on a gram scale employing a previously published^{xx} strategy.




- 10 The procedure follows standard techniques of protection of L-rhamnose (15) by acetylation using acetic anhydride and a catalytic amount of sodium acetate to yield (16) in 68% yield, followed by Lewis Acid aided coupling in a “melt” reaction to form (17) in 5.54% yield. This was followed by standard methanolic deprotection to yield the desired product (18). Protection and deprotection
15 strategies worked well, with respectable yields.

Purification of the final material by washing with water and diethyl ether allowed drying of the product on a freeze drier, which after analysis proved to be pure enough for future use. A slight yellow discolouration is due to the
20 presence of free p-nitrophenol, which is not detected by NMR (<2%).

Example D1 Preparation of 1,2,3,4-tetra-O-acetyl rhamnopyranose:

- 5 L-rhamnopyranose monohydrate (11.10g, 60.9mmol), sodium acetate (5.5g, 67.0mmol) and acetic anhydride (90ml) were stirred in a 250ml round bottom flask fitted with a reflux condenser, and an inert atmosphere was introduced. The mixture was heated using an oil bath with a thermostat set to 110°C for 90 minutes. The mixture was then removed from the heat, and when cool poured
- 10 over ice water (500ml). After allowing to stand for 2 hours, this mixture was extracted with chloroform (3×100ml) and dried overnight over calcium chloride). After filtration, all solvent was removed in vacuo yielding a pale yellow oil, and synthesis proceeded to the next stage without purification.

15 Ex D2 Tri-2,3,4-O-acetyl-p-aminophenyl α -L-rhamnopyranoside:




- Tetra-1,2,3,4-O-acetyl-rhamnopyranose (13.76g, 41.4mmol, from MAR56) and p-nitrophenol (19.264g, 138.4mmol) were combined in 250ml round bottom
- 20 flask and heated at 120°C, under vacuum from a water pump, until all bubbling had subsided. Dry, finely powdered zinc chloride (6.88g, 50.5mmol) was then

added to the now molten mixture, and the vacuum reapplied. The mixture turned from pale yellow to dark brown and was heated for 60 minutes at 120°C, and then cooled to 50°C. This mix was then extracted with chloroform (200ml) and washed with a solution of sodium hydroxide (1M, 3×200ml) and then water (5×200ml). The organic layer was dried over magnesium sulfate and the solvent removed in vacuo.

The resultant brown gum was dissolved in refluxing methanol (120ml), passed over prewashed activated charcoal, filtered, and left to stand overnight. As no precipitation had occurred, some solvent was removed in vacuo, and the solution placed in the freezer overnight. Pale brown crystals formed, which were recrystallised from hot methanol, and a series of crops were taken resulting in the final yield.

Yield: 0.944g, 5.54%. ^1H NMR (CDCl_3 , 199.99Hz): δ 1.21 (d, H×1, H-1), 2.0 2.1 2.2 (s×3, H×3, Ac×3), 3.9 (dq, H×1, H-5), 5.2 – 5.6(m, H×6,), 7.2 (dd, H×2, Ar-H), 8.2 (dd, H×2, Ar-H). ESMS Required peak 434, observed peak 434.

Ex D3 Preparation of p-nitrophenyl α -L-rhamnopyranoside:




Per-O-acetyl p-nitrophenyl α -L-rhamnopyranoside (0.944g, 2.39mmol) was dissolved in dry methanol (25ml) in a 100ml round bottom flask, to which sodium methoxide (1.5ml, 0.1M) was added. The mixture was refluxed for 15 minutes, until the reaction was complete, and then taken to dryness in vacuo.

- 5 The ethanol was removed in vacuo. The resultant solid was dissolved in water, and washed with diethyl ether to remove p-nitrophenol. The water was removed by the use of a freeze dryer, yielding an off-white product.

Elemental Analysis: Theoretical: C 50.53%; H 5.30%; N 4.91% Actual: C 48.92%; H 5.52%; N 5.38%. ^1H NMR (CDCl_3 , 499.99Hz): δ 1.081 (d, H \times 3, H-6 \times 3), 3.386 (t, H \times 1,), 3.58 (dq, H \times 1, H-5), 3.876 (dd, H \times 1, H-2), 4.046 (d, H \times 1, H-1), 7.115 (d, H \times 2, Ar-H \times 2), 8.122 (d, H \times 2, Ar-H \times 2). $[\alpha]_D^{23.5} = -164.87$ (MeOH, c = 0.19). Mpt $^\circ$ = 171.4 – 173.0 $^\circ$ C.

15 E Prodrug Release: Enzyme Kinetic Study:



An aqueous naringinase solution (10 μ l, 0.5mgml $^{-1}$) was tested for catalytic activity against a range of concentrations of p-nitrophenyl α -L-rhamnopyranoside solutions (190 μ l, 3.5, 3.0, 2.5, 2.0, 1.5, 1.0, 0.5, 0.25mM in 0.2M orthophosphate buffer - pH 6.8, 7.0, 7.2).

The substrate solution was pipetted into wells on a multiwell plate, and incubated at 37 $^\circ$ C for 5 minutes. The naringinase solution was then added, and the absorbance read at 405nm for 10 minutes, at 6 second intervals with

shaking for 5 seconds before the start of reading, and 1 second before each individual reading.

F Enzyme stability

5

Heat Stability Studies:

Prior to testing using the above procedure, the enzyme solution was incubated in a water bath at the desired temperature for the appropriate length of time.

10

Organic Solvent Stability Studies:

In addition to testing using the general procedure, the enzyme was introduced to the desired organic solvent (with predetermined organic/aqueous ratio) for a set period of time.

15

Proteolytic Stability of Naringinase

Naringinase is to be used as part of a bipartate drug mechanism and so its ability to withstand the attack of proteases is essential to the success of the system. To this end a protocol has been developed whereby a naringinase solution is treated with a 5% equivalent solution of Subtilisin Bacillus Lentis, and after various incubation periods the naringinase solution was employed in a standard kinetic assay. As deglycosylated naringinase is to be used in further reglycosylation studies, this deglycosylated naringinase was also tested in the same manner. Wild type naringinase proved to be fairly stable to protease activity, with only slight loss of activity over the 48 hour period.

20
25

Kinetic assays

Assays showed that glycosylation does not adversely affect lectin directing activity

An aqueous naringinase solution (10 μ l) was tested for catalytic activity against
5 a range of concentrations of p-nitrophenyl α -L-rhamnopyranoside solutions (190 μ l, 3.5, 3.0, 2.5, 2.0, 1.5, 1.0, 0.5, 0.25mM in 0.2M orthophosphate buffer - pH 6.8, 7.0, 7.2).

The substrate solution was pipetted into wells on a multiwell plate, and
10 incubated at 37°C for 5 minutes. The naringinase solution was then added, and the absorbance read at 405nm for 10 minutes, at 6 second intervals with shaking for 5 seconds before the start of reading, and 1 second before each individual reading.

15 In addition, during heat stability studies, the enzyme solution was incubated in a water bath at the desired temperature for the appropriate length of time before use.

Absorbance data was measured using a UV-vis spectrometer, converted to rate
20 information in MS Excel and then kinetic parameters determined using GraFit 4 from Erithacus Software.

Full kinetic parameters were determined for N-WT \rightarrow N-DG and N-DG \rightarrow GalIME, N-WT, N-WT-GalIME and N-WT-ManIME. N-DG shows
25 greater rate of reaction than N-WT and its ability to bind to substrates is similar resulting in a more active enzyme, attributed to removing obstructing glycosyl groups, with no change in stability or conformation.

N-WT, N-WT-GalIME and N-WT-ManIME were found to be stable at 60°C
30 (greater than physiological temperature) and at physiological pH

G In vivo biodistribution assessment

Preparation of radiolabelled enzyme samples

5

The enzyme samples (10mg) were radiolabelled by the attachment of ^{125}I using Pierce IODO-GEN[®] Pre-Coated Iodination Tubes. The borosilicate tubes are coated with the iodination reagent (1,3,4,6-tetrachloro-3 α -6 α -diphenylglycouril) and supplied ready for use. ^{125}I was purchased from
10 Amersham, and the Direct Method procedure as detailed by Pierce followed. Excess reagent was removed by passing samples through Sephadex PD10 desalting columns.

Radioactivity in each sample was determined at this stage, and final dose
15 calculated.

In vivo testing in male Wistar rats showed enzyme activity in liver.

Example H

20

1 Introduction

The identification, investigation and implementation of significantly improved protein purification methods to our system, which allows the production of
25 reasonable amounts of pure protein (rhamnosidase activity), have been achieved.

Modifications have been carried out on this pure protein to produce a range of constructs.

30

Analysis of these constructs has involved gel electrophoresis and enzyme activity. In addition analysis of their stability in solution, to temperature (hot and cold) and to protease enzymes, has been assessed.

- 5 The *in vivo* assessment work has involved the use of gamma scintigraphy to allow visualisation of the drug in the body. *In vivo* assessment at the cellular level has involved a micro autoradiography study coupled with confocal microscopy. Both allow an assessment of cell-specific delivery of the protein construct to particular cell types within the liver. In addition, confocal
- 10 microscopy using a rhamnopyranosidic fluorophore has allowed an assessment of prodrug mimic activation.

- Stability testing has involved the use of a rat tritosomal preparation^{xxi} to assess the potential stabilities of both protein construct and prodrug in liver
- 15 lysosomes.

2 Methods & Discussion

20 2.1 Enzyme purification

2.1.1 Purification of N-WT (wild-type naringinase)

- Naringinase from *P. decumbens* (200mg) was dissolved in deionised water
- 25 (20ml), placed in cellulose ester dialysis tubing (50kDa MWCO) and dialysed against deionised water for 24 hours (water changes at 1,3,6, 18 hours). Water was removed by freeze-drying yielding a white solid. Yield = 150mg.

2.1.2 Preparation of N-DG (deglycosylated naringinase)

A solution of N-WT (10ml, 10mg/ml in 10mM pH6.0 orthophosphate buffer) and a solution of EndoH (50µl, 10mg/ml solution) were combined in a sample vial fitted with a magnetic stirrer bar and heated at 37°C for 24 hours. The solution was transferred to a Spectrum DispoDialyser® (50 kDa MWCO) and dialysed against deionised water for 24 hours, with water changes at 1, 4, 6 and 18 hours. The resultant solution was freeze-dried yielding a white powder. Purity was assessed by gel electrophoresis (SDS PAGE).

2.1.3 Stability testing

2.1.3.1 Assessment of stability of N-WT during dialysis/freezing/thawing/drying

N-WT (80mg) was dissolved in water (8ml) and dialysed using a SpectraPor DispoDialyser (50kDa MWCO) against water for 24 hours. Three 500µl aliquots were taken from the resultant solution and treated as follows:

1. No further treatment, assessment of composition by 10% SDS PAGE
2. Sample frozen, thawed, assessment of composition by 10% SDS PAGE
3. Sample freeze-dried, assessment of composition by 10% SDS PAGE

For results see Figure 1. The left-hand lane in the Figure shows molecular weight markers.

2.1.3.2 Solution stability of N-WT at room temperature

A solution of N-WT (10ml, 5mg/ml) in orthophosphate buffer (pH7.0, 0.1M) was stirred slowly in a 50ml round bottom flask for 14 days at room
5 temperature. Aliquots were taken at the periods shown, diluted to 0.5mg/ml and a kinetic assay carried out (pH6.8, 7.0, 7.2, with pNP-Rha as substrate).

Sample times: 1, 2, 3, 5, 7, 9, 14 days

10

2.1.3.3 Solution stability of N-WT at 37°C

A solution of N-WT (10ml, 5mg/ml) in orthophosphate buffer (pH7.0, 0.1M) was stirred slowly in a 50ml round bottom flask for 14 days at 37°C. Aliquots
15 were taken at the periods shown, diluted to 0.5mg/ml and a kinetic assay carried out (pH6.8, 7.0, 7.2, with pNP-Rha as substrate).

Sample times: 1, 2, 3, 5, 7, 9, 14 days

20

2.1.3.4 Solution stability of N-WT in the presence of SBL

A solution of N-WT (10ml, 5mg/ml) in orthophosphate buffer (pH7.0, 0.1M) was stirred slowly in a 50ml round bottom flask with an aliquot of SBL
25 solution (1mg, pre-prepared in pH7.0 orthophosphate buffer, freeze dried) for 14 days. Aliquots were taken at the periods shown, diluted to 0.5mg/ml and a kinetic assay carried out (pH6.8, 7.0, 7.2, with pNP-Rha as substrate).

Sample times: 1, 2, 3, 5, 7, 9, 14 days

30

2.1.4 Size Exclusion Chromatography

2.1.4.1 BioGel™ P-2 column (4×70cm) purification of N-WT

5 N-WT (50mg, 10mg/ml in 0.1M sodium chloride corrected to pH4.8 with hydrochloric acid) was loaded onto to a column of BioGel™ P-2 (4×70cm) and eluted using 0.1M sodium chloride corrected to pH4.8 with hydrochloric acid. Fractions (5ml) were collected and analysed by assessing absorbance at
10 280nm and for rhamnosidase and glucosidase activity using pNP-Rha and pNP-Glc substrates (100µl from column plus 100µl 3.5mM substrate solutions, incubated at 37°C). The results are shown in Figure 2.

Fractions 21-27, 28-37 and 39-40 were combined, freeze-dried, redissolved and
15 passed down a Sephadex PD10 desalting column and applied to 10% SDS PAGE.

2.1.4.2 BioGel™ P-100 column purification of N-WT

20

2.1.4.2.1 3.5×50cm column

N-WT (50mg, 8mg/ml in 0.1M sodium chloride corrected to pH4.8 with hydrochloric acid) was loaded onto to a column of BioGel™ P-100
25 (3.5×50cm) and eluted using 0.1M sodium chloride corrected to pH4.8 with hydrochloric acid. Fractions (5ml) were collected and analysed by assessing absorbance at 280nm and for rhamnosidase and glucosidase activity using pNP-Rha and pNP-Glc substrates (100µl from column plus 100µl 3.5mM substrate solutions, incubated at 37°C). The results are shown in Figure 3.

N.B. For 2.1.4.2.1, the sample of N-WT was dialysed (50kDa MWCO) against water prior to application to the column.

- 5 Fractions 19, 21, 23, 26 and 27 were then passed down a Sephadex PD10TM desalting column and analysed by 10% SDS PAGE (Figure 4).

2.1.4.2.2 5.5×45cm column

- 10 N-WT (150mg, 10mg/ml in 0.1M sodium chloride corrected to pH4.8 with hydrochloric acid) was loaded onto to a column of BioGelTM P-100 (5.5×45cm) and eluted using 0.1M sodium chloride corrected to pH4.8 with hydrochloric acid. Fractions (10ml) were collected and analysed by assessing absorbance at 280nm and for rhamnosidase and glucosidase activity using
- 15 pNP-Rha and pNP-Glc substrates (100µl from column plus 100µl 3.5mM substrate solutions, incubated at 37°C). The results are shown in Figure 5.

2.1.4.2.3 5.5×50cm column

- Predialysed (see section 2.2) N-WT (150mg, 10mg/ml in 0.1M sodium chloride
- 20 corrected to pH4.8 with hydrochloric acid) was loaded onto to a column of BioGel P-100TM (5.5×50.0cm) and eluted using 0.1M sodium chloride, corrected to pH4.8 with hydrochloric acid. Fractions (15ml) were collected and analysed by assessing absorbance at 280nm and for rhamnosidase and glucosidase activity using pNP-Rha and pNP-Glc substrates (100µl from
- 25 column plus 100µl 3.5mM substrate solutions, incubated at 37°C for 2 minutes). Appropriate fractions were combined, freeze-dried and desalted using Sephadex G25TM (PD10 column).

2.1.4.2.4 2.5×75cm column

Predialysed (see section 2.2) N-WT (150mg, 10mg/ml in 0.1M sodium chloride corrected to pH4.8 with hydrochloric acid) was loaded onto to a column of BioGel P-100 TM (2.5×75.0cm) and eluted using 0.1M sodium chloride, 5 corrected to pH4.8 with hydrochloric acid. Fractions (12ml) were collected and analysed by assessing absorbance at 280nm and for rhamnosidase and glucosidase activity using pNP-Rha and pNP-Glc substrates (100µl from column plus 100µl 3.5mM substrate solutions, incubated at 37°C for 2 minutes). Appropriate fractions were combined, freeze-dried and desalted using 10 Sephadex G25 (PD10 column).

2.1.4.2.5 3.2×50.0cm – Millipore Vantage-L TM column

Predialysed (see section 2.2) N-WT (250mg, 20mg/ml in 0.1M sodium chloride 15 corrected to pH4.8 with hydrochloric acid) was loaded onto to a column of BioGel P-100 TM (3.2×50.0cm – Millipore Vantage-L TM chromatography column) and eluted using 0.1M sodium chloride, corrected to pH4.8 with hydrochloric acid (flow rate = 20ml/hr, controlled using a peristaltic pump). Fractions (15ml) were collected and analysed by assessing absorbance at 20 280nm and for rhamnosidase and glucosidase activity using pNP-Rha and pNP-Glc substrates (100µl from column plus 100µl 3.5mM substrate solutions). Appropriate fractions were combined, freeze-dried and desalted using Sephadex G25 TM (PD10 column). The results are shown in Figure 6.

2.1.5 Ion Exchange Chromatography

2.1.5.1 Ion Exchange using standard column

5 Product of size exclusion purification (2.4ml, 5mg/ml in 20mM L-histidine buffer, corrected to pH6.0) was loaded onto a column of SepharoseTM DEAE (2.0×25.0cm) and eluted with 20mM L-histidine buffer, corrected to pH6.0 (100ml, 15ml fractions). An increasing salt gradient (0.05 – 0.35M NaCl, 30ml of each incremental 0.05M step) was applied and fractions (15ml) were
10 collected and analysed by assessing absorbance at 280nm and for rhamnosidase and glucosidase activity using pNP-Rha and pNP-Glc substrates (100µl from column plus 100µl 3.5mM substrate solutions). Appropriate fractions were combined, freeze-dried and desalted using Sephadex G25TM (PD10 column). The results are shown in Figure 7.

15

2.1.5.2 Ion Exchange using MilliporeTM column

Product of size exclusion purification (see section 2.3) (2.4ml, 5mg/ml in 20mM L-histidine buffer, corrected to pH6.0) was loaded onto a column of SepharoseTM DEAE (2.0×25.0cm - Millipore Vantage-LTM chromatography
20 column) and eluted with 20mM L-histidine buffer (flow rate = 100ml/hr, controlled using a peristaltic pump), corrected to pH6.0 (100ml, 15ml fractions). An increasing salt gradient (0.05 – 0.35M NaCl, 30ml of each incremental 0.05M step) was applied and fractions (15ml) were collected and analysed by assessing absorbance at 280nm and for rhamnosidase and
25 glucosidase activity using pNP-Rha and pNP-Glc substrates (100µl from column plus 100µl 3.5mM substrate solutions). Appropriate fractions were combined, freeze-dried and desalted using SephadexTM G25 (PD10 column). The results are shown in Figure 8.

30

Summary of enzyme purification work

Initially, yielding a pure band of rhamnosidase activity from crude naringinase (without glucosidase activity or other protein contaminants) was proving
5 difficult, and so this purification was a priority for the project.

Previous purification (prior to glycosylation) had involved dialysis (2.1.1) using cellulose ester tubing with a 50kDa MWCO. This purifies the naringinase to a certain extent, but still not sufficient for the requirements of a drug delivery
10 system.

One explanation for the constant presence of contaminants was that the naringinase was decomposing during handling so a number of assays were carried out. The work described in section 2.1.3.1 was designed to assess the
15 effect of the standard dialysis/freeze/thawing/drying procedures which are routinely carried out on the samples. Analysis in this case was entirely by SDS PAGE (Figure 1) that illustrates that these different techniques show no adverse effects to the protein.

20 Further analysis work was intent on assessing solution stability of naringinase – at room temperature, 37°C and with a protease (SBL). These assays were designed to allow an assessment of stability to handling (i.e. in solution) but also to investigate potential problems when used as in drug delivery – having a substance that is unstable in solution is unsuitable for drug delivery. Results
25 show that, although some loss of activity is observed, this is not a major problem.

In order to improve the quality of purification, a number of different techniques have been investigated. Size exclusion chromatography using BioGel TM media
30 is the first of those stages. BioGel P-2 TM is a resin with a low exclusion limit

(2kDa) and was used as an early comparison. As can be seen (Error! Reference source not found.) little separation of the components of the naringinase mixture is observed – as predicted for a resin with such a low exclusion limit.

5 BioGel P-100 TM is from the same family of resins, but with a much larger exclusion limit (80-100kDa). This affords a significantly improved level of purification. The gel of fractions from 2.1.4.2.1 (Figure 4) shows that it is possible to purify bands in particular weight ranges. In particular fraction 23, which showed greatest rhamnosidase activity is significantly different to the
10 wild type sample, in that the higher molecular weight bands are more prominent, suggesting that we have removed much of the lower molecular weight contaminant from the crude mixture.

A number of different columns were then analysed using the same BioGel P-
15 100 TM resin. Different widths and heights have been assessed (2.1.4.2.2, 2.1.4.2.3 & 2.1.4.2.4), each having little effect on the quality of separation. A move to using Millipore Vantage-L TM columns allowed the use of a peristaltic pump to pump solvent through the column (previous purifications had been run under gravity or using air pressure). This new column allowed more repeatable
20 purifications to be carried out (3.1.4.2.5), although no significant improvement in separation quality was observed.


Ion exchange chromatography was investigated, using samples from the size exclusion chromatography that were most concentrated in rhamnosidase
25 activity. Initial attempts used a standard chromatography column and pure samples of rhamnosidase activity were produced. The use of a Millipore Vantage-L TM column allowed routine use of this resin to yield significant amounts of pure rhamnosidase activity (see gel in modifications section, Figure 9).

A purification method is now available which allows 500mg crude naringinase to yield 30mg pure rhamnosidase activity, after dialysis, size exclusion chromatography and ion exchange chromatography.

5 2.2 Enzyme modification

2.2.1 Preparation of modification reagents


2.2.1.1 Synthesis of Gal-TPU derivative



10

Acetobromo- α -D-galactose (5.0g, 12.16mmol) and thiourea (1.2g, 15.81mmol) were suspended in dry acetone (50ml) in a 250ml round bottom flask fitted with a magnetic stirrer and reflux condenser, under a nitrogen atmosphere. The mixture was refluxed for 2 hours and the reaction followed by tlc, reduced in volume (to 30ml) *in vacuo* and chilled for 3 hours. The resulting white crystals (11) were filtered, washed with cold acetone and dried. Yield = 4.06g. Characterisation as described above.


15



20 2.2.1.2 Synthesis of Gal-IME reagent

- Gal-TPU (3.7g, 7.6mmol) was stirred with dry acetone (20ml) and water (20ml) was added. Sodium bisulfite (2.0g, 38mmol), potassium carbonate (1.6g, 11.5mmol) and chloroacetonitrile (2.5ml, 40mmol) were then added in order, and the mixture stirred at room temperature for 3 hours. This mixture was then added to ice water (50ml) and stirred vigorously for 3 hours at 4°C. Extraction with chloroform (4×40ml) was performed and the extract washed with sodium chloride solution (2×60ml, 1M), and the resulting organic layer was dried over anhydrous magnesium sulfate. The organic solution was filtered and all solvent removed *in vacuo*.
- The resulting gum/crystalline material was purified by flash column chromatography (3:1 EtOAc:Hexane) and the appropriate fractions combined and solvent removed *in vacuo*. Yield = 2.05g, 67%. Characterisation as described above.


2.2.1.3 Synthesis of per-*O*-acetomannose



- Mannose (4.0g, 22.2mmol), pyridine (40ml) and acetic anhydride (20ml) were stirred in a 250ml round bottom flask at room temperature under an inert atmosphere for 24 hours. All solvent was removed *in vacuo*, HCl (15ml, 2M) was added, and then product extracted into ethyl acetate (3×20ml). The combined organic layers were washed with water (3×10ml), dried over magnesium sulfate and then all solvent removed *in vacuo*. Characterisation as described above.

This crude product was used immediately in the next stage (2.1.4.2).

2.2.1.4 Synthesis of acetobromomannose




5

Per-*O*-acetomannose (8g, 20.49mmol), HBr in acetic acid (20ml, 30%) and acetic anhydride (10ml) were stirred in a 250ml round bottom flask under an atmosphere of nitrogen for 24 hours. Additional HBr in acetic acid (5ml, 30%) was introduced and stirring continued for a further 24 hours. Toluene (30ml) and acetic anhydride (5ml) were added, and all solvent removed *in vacuo*, yielding a dark brown syrup. Flash column chromatography (2:1 EtOAc:Hex) yielded pure product (6.0g, 13.59mmol, 66.3%). Characterisation as described above.

15

2.2.1.5 Synthesis of Man-TPU derivative




Acetobromomannose (2.677g, 6.51mmol) and thiourea (0.655g, 8.60mol) were suspended in acetone (25ml, dry) and refluxed under an inert atmosphere for 3.5 hours. The resultant solution was reduced in volume (~30%) and chilled to promote crystallisation of product. Crystallisation was achieved after 36 hours,

20


solid was filtered, washed with dry cold acetone and dried *in vacuo*. Yield = 1.3g, 3.32mmol (51.0%). Characterisation as described above.

5 2.2.1.6 Synthesis of Man-IME derivative



Man-TPU reagent (5.413g, 13.83mmol) was dissolved in water (30ml) and acetone (30ml), and then sodium bisulfite (2.4g, 45.6mmol), potassium carbonate (2.33g, 16.92mmol) and chloroacetonitrile (7.2ml, 115.2mmol) were added in order. The resultant mixture was stirred for 6 hours. The mixture was poured into ice water (50ml) and stirred for 1 hour, and a white precipitate formed. Extraction by chloroform (3×80ml), washing with sodium chloride solution (3×40ml, 1M) and flash column chromatography (3:1 EtOAc: Hexane) yielded a white solid. Yield = 3.539, 8.81mmol (63.7%). Characterisation as described above.

2.2.1.7 Synthesis of N-Benzyl-4-cyanomethylsulfanyl-butylamide




Benzylamine (0.55ml, 5.0mmol), γ -thiobutyrolactone (0.87ml, 10.0mmol) and chloroacetonitrile (1.58ml, 25mmol) were added to an aqueous solution of sodium hydrogen carbonate (30ml, 0.5M) and methanol (25ml) in a round bottom flask fitted with reflux condenser, magnetic stirrer bar and inert
5 atmosphere. The mixture was heated overnight at 50°C.

The methanol was removed *in vacuo*, and the resultant aqueous layer extracted with chloroform (3×60ml). The organic layers were combined and washed with hydrochloric acid (3×60ml, 1M) then dried over magnesium sulfate. This
10 solution was filtered, and all solution removed *in vacuo*.

The product oil was purified by flash chromatography (3:1 EtOAc:Hexane + 1% Et₃N).

15 Yield = 0.57g, 46%. ¹H-NMR (250MHz CDCl₃) δ 2.04 (quin, 2H, H¹⁰), 2.36, 2.80 (2xt, 2×2H, H⁹ & H¹⁰), 3.28 (s, 2H, H¹²), 4.43 (d, 2H, H⁷), 5.85 (s, 1H, NH), 7.26-7.31 (5xs, 5H, Ph).

2.2.1.8 Synthesis of glycodendrimer-IME reagent



5


Bis{N-[2-(1-thio-β-D-galactopyranosyl)ethanoyl]aminoethyl}amine (98.9mg, 0.16mmol), γ-thiobutyrolactone (0.14ml, 1.6mmol) and chloroacetonitrile (0.20ml, 3.2mmol) were added to an aqueous solution of sodium hydrogen carbonate (1ml, 0.5M) and methanol (1ml) in a round bottom flask fitted with reflux condenser, magnetic stirrer bar and inert atmosphere. The mixture was heated for 24 hours at 50°C.

The mixture was neutralized with 2M HCl, concentrated *in vacuo* and purified by flash chromatography (CHCl₃: MeOH:H₂O:Et₃N 60:35:7:1) to yield a product, which was taken to dryness *in vacuo*. The product was then loaded onto Dowex 50W2-200 (H⁺) in water: methanol 1:1 and eluted with 10% NH₃ solution. The product dried by freeze-drying.

Yield = 54.7mg, 45%. ¹H NMR (300MHz, CD₃OD) ~1.25 (t, 4H, CH₂CN), 2.18 (q, 2H), 2.5 (t, 2H), 2.7 (t, 4H), 2.9 (dd, 2H), 3.35 (m, 24H), 4.47 (d, 2H, anomeric H). Mass confirmed by ES-MS.

2.2.1.9 Scale up of 2.2.1.8

- 5 Repeat of 2.2.1.8 but on 300mg scale. Same percentage yield achieved.

2.2.1.10 Synthesis of Peraceto-*O*-lactopyranose


10

Lactose monohydrate (16.0g, 44.4mmol) was suspended in acetic anhydride (64ml, 678.4mmol) and pyridine (128ml, 1.56mol). The mixture was stirred for 24 hours at room temperature under an inert atmosphere. All solvent was removed *in vacuo* yielding an orange oil which was washed with hydrochloric acid (50ml, 2M) and extracted with ethyl acetate (4×70ml). Organic layers were combined and washed with water (3×30ml) then dried over anhydrous magnesium sulfate. All solvent was removed *in vacuo* yielding a pale yellow gum.

20 Yield = 35.5g, 50.1mmol = 113%

This product was used crude in the next step, 2.2.1.11.

2.2.1.11 Synthesis of acetobromolactopyranose




Peraceto-*O*-lactopyranose (30.9g, 44.4mmol) was dissolved in dry
 5 dichloromethane (200ml) and hydrogen bromide in acetic acid (60ml, 30%)
 was added dropwise. After 3 hours the solution was poured over ice water, then
 organic and aqueous layers separated. The organic layer was washed with a
 saturated solution of sodium hydrogen carbonate (3×50ml), dried over
 anhydrous magnesium sulfate, filtered and all solvent removed *in vacuo*
 10 yielding a brown oil. Flash column chromatography (2:1 ethyl acetate: hexane)
 was unsuccessful.

2.2.2 Modification reactions

15

2.2.2.1 Preparation of N-WT→GalIME



20 Cyanomethyl Per-*O*-acetyl-1-thiogalactopyranoside (270mg, 0.67mmol) was
 dissolved in dry methanol (24ml) in a 50ml r.b.f. fitted with a magnetic stirrer
 under an inert atmosphere. A methanolic solution of sodium methoxide (240μl,


1M) was added and stirring continued at room temperature for 36 hours. All solvent was removed *in vacuo* yielding a white solid.

N-WT (50mg) was dissolved in an aqueous solution of sodium tetraborate
 5 (0.25M, pH8.5) and added to the white solid and stirred at room temperature for 24 hours.

The solution was then dialysed against deionised water for 12 hours (with water changes at 1, 4, and 6 hours) using ViskinTM dialysis tubing (12-14kDa),
 10 and then passed down a Sephadex G25 PD10TM column. The resultant solution was freeze-dried yielding a white powder.

2.2.2.2 Preparation of N-WT→ManIME

15




Cyanomethyl Per-O-acetyl-1-thiomannopyranoside (225mg, 0.56mmol) was dissolved in dry methanol (20ml) in a 50ml r.b.f. fitted with a magnetic stirrer
 20 under an inert atmosphere. A methanolic solution of sodium methoxide (200μl, 1M) was added and stirring continued at room temperature for 36 hours. All solvent was removed *in vacuo* yielding a white solid.

N-WT (40mg) was dissolved in an aqueous solution of sodium tetraborate (0.25M, pH8.5) and added to the white solid and stirred at room temperature for 24 hours.

- 5 The solution was then dialysed against deionised water for 12 hours (with water changes at 1, 4, and 6 hours) using Viskin™ dialysis tubing (12-14kDa), and then passed down a Sephadex G25 PD10™ column. The resultant solution was freeze-dried yielding a white powder.

10

2.2.2.3 Preparation of N-WT→dGalIME



15

Cyanomethyl dendriGal (510mg, 0.67mmol) was dissolved in dry methanol (37ml) in a 100ml r.b.f. fitted with a magnetic stirrer under an inert atmosphere. A methanolic solution of sodium methoxide (375μl, 1M) was added and stirring continued at room temperature for 36 hours. All solvent was removed *in vacuo* yielding a white solid.


20

N-WT (50mg) was dissolved in an aqueous solution of sodium tetraborate (0.25M, pH8.5) and added to the white solid and stirred at room temperature for 24 hours.

- 5 The solution was then dialysed against deionised water for 12 hours (with water changes at 1, 4, and 6 hours) using ViskinTM dialysis tubing (12-14kDa), and then passed down a Sephadex G25 PD10TM column. The resultant solution was freeze-dried yielding a white powder.

10

2.2.2.4 Preparation of N-DG→GalIME



- 15 GalIME reagent (155mg, 0.38mmol) was dissolved in dry methanol (14ml) in a 100ml round bottom flask fitted with a magnetic stirrer under an inert atmosphere. A methanolic solution of sodium methoxide (28ml, 0.01M) was added, and the mixture stirred for 36 hours at room temperature.

- 20 The contents of the flask were taken to dryness *in vacuo*, and a solution of N-DG (35mg, 10mg/ml in 0.25M sodium borate, pH8.5 corrected with cHCl) was added. The mixture was stirred under a nitrogen atmosphere for 24 hours. After this time, the solution was purified by Biogel P-2TM column (2×60cm, 0.1M NaCl, pH4.8) with presence of protein detected by spectroscopy (absorbance at
25 280nm). Appropriate fractions were combined and freeze dried, resulting in a white powder. Purity was assessed by gel electrophoresis (Figure 9).

1-SDS6 marker	6-N-DG-GalIME
2-N-WT	7-empty
3-N-WT-GalIME	8-N-WT
5-N-DG	9-N-WT-dGalIME

Summary of modifications described in Example H

The synthesis of modification reagents has continued from the work described in Examples A & B. Large amounts (>2g) of the ManIME and GalIME reagents have been synthesised and a sufficient amount of the dendriGalIME reagent is available.

Modification reactions have been continued as previously described, but now with pure rhamnosidase activity as opposed to the crude bands previously used. Analysis after modification (Figure 9) shows the changes in weight achieved and also the purity of the constructs.

2.3 Enzyme assay

2.3.1 pH curve of N-WT

5 An aqueous solution of N-WT (10 μ l, 0.5mg/ml) was tested for catalytic activity against a range of concentrations of *p*-nitrophenyl α -L-rhamnopyranoside solutions (190 μ l, 3.5, 3.0, 2.5, 2.0, 1.5, 1.0, 0.5, 0.25mM in 0.1M orthophosphate buffer - pH 5.8, 6.0, 6.2, 6.4, 6.6, 6.8, 7.0, 7.2, 7.4, 7.6, 7.8, 8.0).

10

The substrate solution was pipetted into wells on a multiwell plate, and incubated at 37°C for 5 minutes. The naringinase solution was then added, and the absorbance read at 405nm for 5 minutes, at 6 second intervals with shaking for 5 seconds before the start of reading, and 1 second before each individual
15 reading. The results are shown in Figure 10.

2.3.2 pH curve of N-DG

20 An aqueous solution of N-DG (10 μ l, 5.0mg/ml) was tested for catalytic activity against a range of concentrations of *p*-nitrophenyl α -L-rhamnopyranoside solutions (190 μ l, 3.5, 3.0, 2.5, 2.0, 1.5, 1.0, 0.5, 0.25mM in 0.1M orthophosphate buffer - pH 5.8, 6.0, 6.2, 6.4, 6.6, 6.8, 7.0, 7.2, 7.4, 7.6, 7.8, 8.0).

25

The substrate solution was pipetted into wells on a multiwell plate, and incubated at 37°C for 5 minutes. The naringinase solution was then added, and the absorbance read at 405nm for 5 minutes, at 6 second intervals with shaking

for 5 seconds before the start of reading, and 1 second before each individual reading. The results are shown in Figure 11.

2.3.3 Enzyme Assay

5

An aqueous solution of enzyme sample (10 μ l, 0.5mgml⁻¹) was tested for catalytic activity against a range of concentrations of *p*-nitrophenyl α -L-rhamnopyranoside solutions (190 μ l, 3.5, 3.0, 2.5, 2.0, 1.5, 1.0, 0.5, 0.25mM in 0.2M orthophosphate buffer - pH 6.8, 7.0, 7.2) and also range of

10 concentrations of *p*-nitrophenyl β -D-glucopyranoside solutions (190 μ l, 3.5, 3.0, 2.5, 2.0, 1.5, 1.0, 0.5, 0.25mM in 0.2M orthophosphate buffer - pH 6.8, 7.0, 7.2)

The substrate solution was pipetted into wells on a multiwell plate, and

15 incubated at 37°C for 5 minutes. The enzyme solution was then added, and the absorbance read at 405nm for 10 minutes, at 6 second intervals with shaking for 5 seconds before the start of reading, and 1 second before each individual reading.

	$V_{\max} / \text{Ms}^{-1}$	K_m / M	$k_{\text{cat}} / \text{s}^{-1}$	$k_{\text{cat}} / K_m / \text{s}^{-1} \text{M}_1$	$\ln \left[\frac{(k_{\text{cat}}/K_m)_{\text{sample}}}{(k_{\text{cat}}/K_m)_{\text{pure WT}}} \right]$
N-WT (Sigma)-pH7.0 Rha	4.10E-08	1.84E-03	0.13	71.2	-0.17
N-WT (dialysed)-pH7.0 Rha	3.22E-07	1.62E-02	0.62	38.2	-0.79
N-WT (pure)-pH7.0 Rha	1.71E-06	3.37E-02	2.84	84.2	0.00

N-WT-GalIME-pH7.0 Rha	6.83E- 07	3.77E- 02	1.14	30.1	-1.03
N-WT-dGalIME- pH7.0 Rha	2.37E- 07	2.32E- 02	0.39	17.0	-1.60

Table 2: Rhamnosidase activities*Summary of enzyme assays*

5

Apart from the standard assays carried out as part of purifications and stability assessments, an investigation into the effect of pH and also assays on some of the new pure constructs have been undertaken. The pH curves show results that could be predicted – as previously shown, a pH optimum at just below

10

7.0, with decreased activity either side of that optimum.

Table 2 Illustrates the effect of purification and modification on the rhamnosidase activity of the samples. See also Figure 12.

15

Glucosidase activity (trace – not able to fit data) was detected in the first two samples – crude preparation from Sigma and after dialysis – but not after further purification (i.e. after ion exchange chromatography).

20

2.4 Poly-L-lysine (PLL) modification*2.4.1 Mass spectral analysis of PLL samples*


25

a) PLL-HBr (~24kDa) was dissolved in deionised water (2mg/ml) and diluted by a factor of one sixth with 1:1 water:acetonitrile (+ 0.5% formic acid).

Samples were analysed on a MicroMass LCTTM via syringe pump introduction.

- b) PLL-HBr (~24kDa) was dissolved in deionised water (2mg/ml) and
 5 desalted using a Sephadex PD10TM column. The appropriate fractions (ninhydrin detection) were collected and combined and diluted by a factor of one sixth with 1:1 water:acetonitrile (+ 0.5% formic acid). Samples were analysed on a MicroMass LCTTM via syringe pump introduction.
- 10 c)) PLL-HBr (~24kDa) was dissolved in deionised water (50mg, 10mg/ml) and dialysed against water using a DispoDialyserTM (2kDa MWCO). The resulting solution was freeze dried. Desalted samples were dissolved in deionised water (2mg/ml) and diluted by a factor of one sixth with 1:1 water:acetonitrile (+ 0.5% formic acid). Samples were analysed on a
 15 MicroMass LCTTM via syringe pump introduction.

2.4.2 Mannose modification of poly-L-lysine – 500:1




Mannose-IME reagent (266mg, 0.66mmol) in dry methanol (60ml) was stirred under a nitrogen atmosphere with methanolic sodium methoxide (4.5ml, 0.1M) for 24 hours. All solvent was removed *in vacuo*.

Poly-L-lysine hydrobromide (50mg, MW \approx 24kDa) was dissolved in sodium tetraborate solution (5ml, 0.25M, pH8.5), added to the residue from the first stage and stirred at room temperature for 36 hours. An off-white precipitate formed, and so further sodium tetraborate solution (75ml, 0.25M, pH8.5) was added to aid dissolution before dialysis.

The solution was then dialysed using SpectraPor Cellulose EsterTM dialysis tubing (12-14kDa MWCO) for 24 hours, against deionised water, and then freeze-dried yielding a white powder.

2.4.3 Mannose modification of poly-L-lysine – 100:1



Mannose-IME reagent (53mg, 0.13mmol) in dry methanol (60ml) was stirred under a nitrogen atmosphere with methanolic sodium methoxide (4.5ml, 0.1M) for 24 hours. All solvent was removed *in vacuo*.

Poly-L-lysine hydrobromide (50mg, MW \approx 24kDa) was dissolved in sodium tetraborate solution (5ml, 0.25M, pH8.5), added to the residue from the first stage and stirred at room temperature for 24 hours.

The solution was then dialysed using a SpectraPor DispoDialyserTM (2kDa MWCO) for 24 hours, against deionised water, and then freeze-dried yielding a white powder.

5

2.4.4 NMR analysis of mannose modifications of poly-L-lysine

The products from experiments 2.4.1 and 2.4.2 were analysed using proton NMR. 20mg of each sample was dissolved in 0.7ml of deuterated H₂O and
10 spectra were acquired on a 250MHz machine. As a reference, non-modified poly-L-lysine was prepared as a sample in a similar way to the modified samples and a spectrum acquired.

15

2.4.5 SDS PAGE of poly-L-lysine samples

Samples of poly-L-lysine, prepared in the standard way for gel electrophoresis, were applied to a 10% SDS PAGE system.

20 No sample was detected on the gel after staining.

2.5 In vivo work – gamma camera imaging

25

A number of radiolabelled constructs (see below) were dosed to New Zealand White rabbits (approximately 1kg) and imaged using gamma scintigraphy to investigate *in vivo* distribution.

Set	Dose	Blocker?	Number of animals
1	N-WT	x	4
2	N-WT→GalIME	x	4
3	N-WT→GalIME	✓ - a	4
4	N-WT→ManIME	x	4
5	N-WT→ManIME	✓ - b	4
6	N-WT→dendriGalIME	x	4
7	N-WT→dendriGalIME	✓ - a	4
Total =			28

a – asialofetuin (100mg/kg)

b – mannosylated polylysine (100mg/kg)

Table 3: Summary of experiment - doses

5

1. Animals were sedated with Hypnorm (intramuscular or subcutaneous).
2. If appropriate, blocker (100mg/kg) was dosed intravenously 10 minutes prior to protein dose.
- 10 3. ¹²³I-labelled^{xxii} xxii protein (2.5mg/kg in 1ml or less of PBS) was dosed intravenously. Total maximum intravenous liquid dose was 2.0ml/kg.
4. A gamma camera was used to image drug distribution over time (0, 10, 30, 60, 90 and 120 minutes post-dose).
5. Blood samples were taken from the ear vein (10, 30, 60 and 120
- 15 minutes post-dose). Sample volumes were in accordance with LASA guidelines (max 4ml/kg).

6. At the end of the study, the animals were sacrificed and drug distribution confirmed via dissection and organ analysis.

The protein constructs (N-WT, N-WT→GalIME, N-WT→ManIME, N-
5 WT→dGalIME) were labelled with ^{123}I using the IODO-GEN technique
(generation of iodonium ion from solution of Na^{123}I with IODO-GEN reagent
allowing electrophilic addition to *ortho* position of tyrosine rings in protein).
 ^{123}I is a gamma emitter with an energy level window appropriate for detection
using gamma scintigraphy. This technique allows an assessment of *in vivo*
10 distribution of the protein construct over a period of time (2 hours). In
addition, standard dissection/organ distribution studies were used to
supplement data from the gamma scintigraphy.

The three modified constructs were each dosed in two sets – with and without
15 a blocker of their particular uptake mechanism. The galactosylated constructs
were blocked with asialofetuin (AF), a known blocker of the
asialoglycoprotein receptor (ASGPR) and mannosylated constructs were
blocked with mannosylated polylysine, both at doses some forty times higher
than the construct dose.

20

Figure 13 allows a visual analysis of the effect of blocking uptake of
galactosylated samples with asialofetuin. By using this blocker in great excess
it is possible to see a change in activity in the liver (and therefore hepatocytes)
25 due to a lack of receptor mediated endocytosis (RME) into the hepatocytes
when blocker is present.

Each hepatocyte has some 500,000 ASGPR's on its surface and so even when
a large excess of blocker is introduced to the animal, this blocking capacity

will eventually diminish. (RME is an active process and the cell takes up the AF, it doesn't simply block a particular receptor for a long period of time).

Due to the limits of dissolution of the AF and the maximum volume that can be injected into an animal, it is necessary to accept that this blocking action
5 has a finite lifetime. This is borne out in the time curves seen from determining standardised activity in the liver.

We can also see the liner residence time over the two hour period of the study (Figures 14 and 15). Initially, whilst the predosed AF is still present and
10 blocking the RME of the galactosylated sample, a marked difference between the samples with and without AF is observed. Through the course of the study (2 hours) as the AF is removed from circulation and its effects become less pronounced this difference is reduced.

15 The amount of activity may reduce due to a number of factors:

1. Initially, some of the activity observed is due to construct circulating in the blood.
2. Some construct, on reaching the liver may be metabolised.
3. The gamma camera pictures show large amounts of construct in the
20 bladder after 2 hours. This is due to a large excess of dose been given. This will clearly affect the ability of the body to selectively take up the construct via RME, and hence the presence of the construct in the bladder as it is excreted renally. This may also effect some non-selective uptake in the liver – perhaps into Kupffer cells which would
25 excrete the construct.

The important observation though is that a difference of delivery with/without blocker is observed and also that some significant activity is retained after two hours.

2.7 *In vivo* work – microautoradiography and confocal microscopy

A: Results/Discussion

2.7.1 Assessment of fluorescence of Tissue Tek OCT™

Tissue Tek OCT is a proprietary product designed for immobilising frozen tissue samples. The medium allows rapid preservation of samples that can be later processed, for example by taking sections on a cryostat microtome, for use in further studies. As fluorescence was to be used for assessing prodrug activation using sections prepared from the Tissue Tek OCT immobilised samples, it was essential to determine that Tissue Tek OCT would not interfere with these studies. A thin layer of Tissue Tek OCT was sandwiched between two microscope slides and fluorescence determined by excitation at 365nm. No fluorescence was observed.

In addition, when focussing the confocal microscope (see later) any residual fluorescence in the sample would have been observed before the rhamnopyranosidic fluorophore was added. The only fluorescence detected at this stage was due to the sample itself – many tissues have low levels of endogenous fluorescence.

2.7.2 ³H-labelling

The use of *N*-succinimidyl-[2,3-³H] propionate to tritiate proteins is a well-established method.^{xxiii} Tritium is the isotope of choice for this microautoradiography study due to its radiation energy providing high resolution of imaging compared to other isotopes. Although supplied as a solution in toluene, the label was used in aqueous solution (toluene having been removed *in vacuo*) at pH8.0. It has been documented^{xxiii} that propionation of lysine residues is achievable at a pH range of 3-8. In addition

tyrosine residues may be propionated at pH8, and as the naringinase constructs are glycosylated through lysine residues, an alkali pH, 8.0, was chosen to facilitate labelling of tyrosine residues. It should be remembered that higher pH values would lead to hydrolysis of the *N*-succinimidyl-[2,3-³H] propionate label before protein labelling had occurred. Extended labelling times of up to 24 hours are possible, though in the interests of protein stability, a reaction time of two hours was used.

10 2.7.3 *In vivo* distribution study

Microautoradiography is a technique often used to determine cellular localisation of agents within the body. The method described here is based on previous *in vivo* studies in this project. A protein dose of 2mg/kg was given to male Wistar rats, with and without a blocking agent, dosed at 100mg/kg. For the galactose modified constructs this blocker was asialofetuin, a known ligand for the asialoglycoprotein receptor, and for the mannose modified constructs this blocker was PLL-Man. The animals were sacrificed 20 minutes post dose and liver and kidneys removed. The liver samples were processed in two ways. Firstly, two 3mm slices were taken from separate lobes, immobilised in Tissue Tek OCTTM on a cork ring and frozen in a solvent bath at -40°C for use in confocal microscopy studies. Secondly, the remaining liver and kidney samples were stored separately in buffered formalin for processing for microautoradiography studies.

25

2.7.4 *Sample processing for micro autoradiography*

The liver and kidney samples stored in buffered formalin were processed for microautoradiography by impregnating with and mounting in wax. This process was achieved using a Tissue Tek VIPTM machine. Once set, the wax

block could be sliced to produce 4 μm thick tissue sections for analysis. These sections were prepared on a microtome, and floated onto Vectabond-coated microscope slides. Once dried, these slides provide a stable basis for further manipulation. The wax has to be removed for autoradiography, and this is
5 achieved by dipping the slides in xylene baths, and an IMS \rightarrow water gradient of baths, replacing all organic residues with water. These slides were then dipped in Ilford nuclear emulsion and stored in the dark before processing.

2.7.5 Confocal microscopy

10 Fluorescent prodrug mimics have been used to probe the activation of prodrugs by naringinase in the liver. This allows an assessment of the activity of naringinase samples once located in the liver and also of construct localisation. As the fluorescent probe, as with future prodrugs, is a rhamnopyranoside, no mammalian enzymes are available to cleave the probe
15 or prodrug. Therefore any fluorescence observed in the system after the prodrug mimic has been added must be due to activation by the delivered construct (naringinase).

Samples were prepared by taking 7 micron slices of the Tissue Tek OCT-immobilised liver samples on a cryostat microtome. These slices were loaded
20 onto a microscope coverslip and then into a chamber designed to fit the confocal microscope. A buffer designed to mimic physiological conditions was layered over the sample, and the microscope focused on the surface of the sample. Scanning images of the surface and fluorescence images were recorded – no significant fluorescence was observed at this stage. A solution
25 of 4-methylumbelliferyl α -L-rhamnopyranoside (50 μl , 2.0mM) was added to the chamber and fluorescence detection continued. In the case of N-DG \rightarrow dGalIME (the only sample assessed to date) fluorescence was detected, and attributed to activation of the prodrug mimic by the construct located in hepatocytes of the liver sample.

Results are shown in Figure 18. Figure 18a shows an image of a section from liver of N-DG→dGalIME dosed animal under phase imaging conditions.


Figure 18b shows the same section in the same orientation under fluorescence imaging conditions with 4-methylumbelliferyl α -L-rhamnopyranoside.

B: Methods

2.7.1 Assessment of fluorescence of Tissue Tek OCT™

Tissue Tek OCT was layered between two microscope slides and placed in a fluorescence spectrometer, excited at 365nm and emission recorded at 375-700nm. As a control, two microscope slides without Tissue Tek OCT was subjected to the same conditions. No fluorescence was detected.

2.7.2 ^3H -labelling



^3H -NSP (4.30mCi, 94.0Ci/mmol, APBiotech TRK556™, Batch 97, 1mCi = 37MBq) was supplied in toluene, which was removed *in vacuo*, and the resultant white solid dissolved in sodium tetraborate solution (6.3ml, 0.1M pH8.0). This solution was added to solutions of protein in sodium tetraborate buffer as detailed in table below. After two hours reaction time, the protein

was purified by size exclusion chromatography using a Sephadex G25 PD10TM column, eluting with phosphate-buffered saline. Radioactivity was determined using scintillation counting.

	Mass protein / mg	Vol protein buffer / ml	Vol radiolabel buffer / ml	Radioactivity / MBq
N-WT	1.5	0.20	0.45	0.32
N- WT→GalIME	3.0	0.40	0.90	0.39
N- WT→ManIME	3.0	0.40	0.90	0.26
N- WT→dGalIME	3.0	0.40	0.90	0.39
N-DG	1.5	0.20	0.45	0.37
N-DG →GalIME	3.0	0.40	0.90	0.32
N-DG →ManIME	3.0	0.40	0.90	0.35
N-DG →dGalIME	3.0	0.40	0.90	0.31

5

2.7.3 *In vivo* distribution study

1. Male wistar rats (approx. 250g) were weighed and tail marked for
10 identification purposes (two animals per dose type).
2. The rats were kept in a hot-box at 38°C for approximately 15 minutes
prior to use to dilate the tail veins.

3. The animals were anaesthetised using a solution of 2ml Hypnorm (fentanyl / fluanisone) + 2ml Hypnovel (midazolam) + 10ml water for injection, via an indwelling needle implanted into the tail vein. 0.2ml of anaesthetic was administered for induction of anaesthesia, and 0.1ml was given as a top-up dose as required in order to maintain anaesthesia throughout the study. The rats were positioned ventral side up on a heated table or mat to maintain body temperature (36-40°C). The rats were surgically prepared by making a midline incision in the neck followed by cannulation of the carotid artery, to allow collection of serial blood samples. 0.25mg/ml heparin in 0.9% saline was instilled into the carotid cannula to prevent clot formation between samples.
4. If appropriate, blocker (100mg/kg in PBS) was dosed intravenously via the tail vein 10 minutes prior to protein dose. (Details of dosing in table below)
5. ³H-labelled protein (2mg/kg, in 1ml or less of PBS) was dosed intravenously. Total maximum intravenous dose (including test substances and anaesthetic) was 5.0ml/kg, in accordance with LASA guidelines.
6. Blood samples were taken from a superficial vein or a previously implanted cannula (if applicable) to produce a concentration-time profile of drug in the blood (0, 1, 5, 10, 15 and 20 minutes post-dose). Maximum total blood sample volume was 6.5ml/kg (equivalent to 10% of total blood in body).
7. At the end of the study, the animals were sacrificed by overdose (Euthatal), and livers and kidneys removed for further analysis. Two 2mm slices were taken from each liver and frozen in Tissue Tek OCT onto a cork disk, and the remainder stored in buffered formalin.

	Asialofetuin	PLL-Man	No. of animals
N-WT	x	x	2
N-WT→GalIME	x	x	2

	✓	×	2
N- WT→ManIME	×	×	2
	×	✓	2
N- WT→dGalIME	×	×	2
	✓	×	2
N-DG	×	×	2
N-DG →GalIME	×	×	2
	✓	×	2
N-DG →ManIME	×	×	2
	×	✓	2
N-DG →dGalIME	×	×	2
	✓	×	2

2.7.4 Sample processing for micro autoradiography

Two 3mm slices were taken from each liver and kidney samples and mounted
 5 into a processing cassette. These cassettes were loaded onto a Tissue Tek VIP
TM machine for a standard wash/wax procedure, then suspended in wax and
 cooled. The surface of the wax blocks was prepared by taking 10 micron thick
 slices on a microtome to reveal the sample tissue, followed by 4 micron thick
 slices which were floated onto the surface of Vectabond TM coated microscope
 10 slides (10 slides per tissue sample were prepared). After being dried overnight
 in an oven at 37°C, the residual wax was removed by dipping in xylene and
 IMS→water gradient tanks. The slides were then coated with Ilford nuclear
 emulsion (range of particle sizes), dried and stored in the dark.

15

2.7.5 Confocal microscopy

Tissue samples stored in Tissue Tek OCT TM were prepared for confocal
 microscopy by taking 7 micron thick slices on a cryostat microtome and

loading on a microscope cover slip. These coverslips were loaded into a confocal microscopy cell and submerged in physiological buffer (500µl, 145mM NaCl, 5mM KCl, 2mM CaCl₂, 1mM MgCl₂, 10mM HEPES, 10mM glucose, pH7.4). Once the microscope had been focused on the section, images were recorded every 8 seconds (Argon laser – 360nm excitation, 405±40nm emission), and a solution of 4-methylumbelliferyl α-L-rhamnopyranoside (50µl, 2mM) added. Fluorescence was detected for a further 2 minutes. A sample of substrate and buffer was imaged as a control reaction.

2.8 Stability Testing

A: Results and Discussion

2.8.1 Tritosome purification

A rat liver tritosomal preparation was produced according to known methods. This preparation is useful for assessing the stability of constructs delivered to the hepatocytes. Galactosylated constructs are actively taken up into the cell in an endosome by the endocytic action of the asialoglycoprotein receptor. These endosomes fuse with lysosomes in the hepatocytes, where they will be exposed to lysosomal enzymes. These enzymes are present in the body to break down foreign bodies and waste material, and contain proteases and glycosidases, amongst others. It is essential that the constructs delivered to the hepatocytes are able to survive this degradation in order that they can act on the delivered prodrug. It is hoped that the glycosylation process used in the modification of the constructs will indeed act to stabilise the constructs to these enzymes.

2.8.2 Assessment of protein content of tritosomal preparation

The Bicinchoninic acid method was used to determine the protein content (and therefore enzyme content) of the tritosomal preparation. By calibrating the sample against a known concentration of BSA, it was shown that the preparation contained protein at a concentration of 0.18mg/ml.

5

2.8.4 Assessment of tritosome activity

2.8.5 Determining extinction coefficient of pNP in tritosomal assay conditions

10 The extinction coefficient of *p*-nitrophenol varies depending on the conditions, particularly pH, in which it is detected. Previous assays have investigated *p*-nitrophenol at pH7.0, and so it was necessary to determine the extinction coefficient in the conditions in which the tritosomal stability tests will be carried out. A solution of *p*-nitrophenol in DMSO was prepared and diluted to
15 gave a concentration gradient in pH5.5 citrate-phosphate buffer with Triton X100, EDTA and GSH. The extinction coefficient of *p*-nitrophenol under these conditions was found to be $511.2\text{M}^{-1}\text{cm}^{-1}$ (Figure 16).

20 *2.8.6 Assessment of tritosomal stability of pNP- α -L-Rha (a)*

One essential facet of the LEAPT concept is that the rhamnoside-capped prodrugs will be cleaved only by the selectively delivered naringinase construct. To ensure that this is possible, a lysosomal tritosome preparation was used to assess the potential cleavage of α -L-rhamnopyranosides by
25 enzymes in the hepatocytes. *p*-Nitrophenyl α -L-rhamnopyranoside was used as a chromogenic prodrug mimic. If there are enzymes present in the hepatocytes capable of cleaving α -L-rhamnopyranosidic linkages, this would be detected over an extended assay by the production of *p*-nitrophenol. Assay conditions based on those used in 2.2.4 were recreated with the used of *p*NP-

α -L-Rha instead of the protease substrate. The mixture was incubated at 37°C and the absorbance at 410nm recorded every 5 minutes. No activity was detected after 30 minutes and so a new study (2.8.7) with a higher concentration of *p*NP- α -L-Rha was designed.

5

2.8.7 Assessment of tritosomal stability of *p*NP- α -L-Rha (b)

With the concentration of *p*NP- α -L-Rha increased ten-fold, the tritosomal stability of rhamnopyranosides was reassessed. There was no production of *p*-nitrophenol after 30 minutes, so the mixture was left at 37°C for 20 hours. After 20 hours, there was no increase in the level of absorbance at 410nm, so we can conclude that α -L-rhamnopyranosides are stable in hepatic lysosomes.

15 2.8.8 Assessment of tritosomal stability of *p*NP- β -D-Gal

Further assessments of the glycosidic enzymes present in the tritosomal preparation were required to allow further design of prodrugs. An assay equivalent to 2.8.7 was used to assess β -D-galactopyranosidic activity. A slight increase in absorbance at 410nm was detected after 30 minutes and so the mixture was left for 20 hours at 37°C. After this time a significant amount of *p*-nitrophenol had been released proving β -D-galactopyranosidic activity.

2.8.9 Assessment of tritosomal stability of *p*NP- β -D-Glc

25 Further assessments of the glycosidic enzymes present in the tritosomal preparation were required to allow further design of prodrugs. An assay equivalent to 2.3.7 was used to assess β -D-glucopyranosidic activity. A slight increase in absorbance at 410nm was detected after 30 minutes and so the

mixture was left for 20 hours at 37°C. After this time a significant amount of *p*-nitrophenol had been released proving β -D-glucopyranosidic activity.

5 2.8.10 Determining extinction coefficient of pNP in pH5.5 citrate-phosphate buffer

The extinction coefficient of *p*-nitrophenol varies depending on the conditions, particularly pH, in which it is detected. Previous assays have investigated *p*-nitrophenol at pH7.0, and so it was necessary to determine the extinction
10 coefficient in the conditions in which the long-term construct stability tests will be carried out. A stock solution of *p*-nitrophenol (0.2M) in citrate-phosphate buffer (0.2M, pH5.5) was diluted to a concentration series and incubated in a multiwell plate (200 μ l) at 37°C. The absorbance at 405nm determined and extinction coefficient calculated to be 521.1M⁻¹cm⁻¹.

15

2.8.11 Determining standard enzyme kinetics of N-WT in pH5.5 citrate-phosphate buffer

A standard enzyme assay of N-WT was carried out, but with a change of
20 buffer conditions to pH5.5 0.2M citrate-phosphate buffer, with and without Triton X100 (used as a detergent to disrupt the lysosomal lipid compartment).

	$V_{\max} / \text{Ms}^{-1}$	K_m / M	$k_{\text{cat}} / \text{s}^{-1}$
MAR317+TritonX100	1.031E-05	4.500E-03	1.71
MAR317-TritonX100	1.203E-05	3.433E-03	2.00

These results are comparable to previous assays involving N-WT, with a slight
25 reduction in k_{cat} easily attributed to the acidic conditions.

2.8.12 Assessment of tritosomal stability of N-WT

N-WT was incubated with tritosome preparation to assess potential stability in hepatic lysosomes. An aliquot was removed at set time points (up to 48 hours) and assessed using a standard assay with pNP- α -L-Rha at pH5.5. The chart in Figure 17 below illustrates the fact that there is little change in kinetic parameters in time, indicating that naringinase is a good candidate for use in LEAPT.

B: Methods

2.8.1 Tritosome purification

Rat liver tritosomes were prepared by a standard procedure.^{xxiv}

2.8.2 Assessment of protein content of tritosomal preparation

The protein content of the tritosome preparation was determined using the Bicinchoninic Acid assay.^{xxv} The BSA calibration chart allowed the concentration of protein in the tritosome preparation to be determined as 0.18mg/ml.

2.8.3 Assessment of bound Nap in stock solution

A stock solution (1.5ml, pH5.5 citrate phosphate buffer plus 0.2% Triton X100 and 50mM reduced glutathione and 10mM EDTA) and DMSO (5 μ l) were mixed in a cuvette and used to blank the spectrometer at 315nm. A solution of BzPheValArgNap (5 μ l, 7.0 mg/ml, 1.09×10^{-5} mol/ml) in DMSO was then added to stock solution (1.5ml) in a separate cuvette and the absorbance at 315nm determined.

2.8.4 Assessment of tritosome activity

A stock solution was prepared (pH5.5 citrate phosphate buffer plus 0.2% Triton X100 and 50mM reduced glutathione (GSH) and 10mM EDTA) and used as a basis to prepare EDTA (10mM) and reduced glutathione (50mM) solutions. Three cuvettes (one blank and two assays, as in table below) were used to determine the tritosome activity by reading absorbance at 410nm (substrate solution is BzPheValArgNap in DMSO 7.0 mg/ml, 1.09×10^{-5} mol/ml) in a chamber incubated at 37°C.

10 a) Cuvette setup

	Blank – volume / μ l	Assay – volume / μ l
10mM EDTA	100	100
50mM GSH	100	100
Substrate solution	30	30
Stock solution	740	740
Tritosomes	0	30
DMSO	30	0

b) Readings from spectrometer

Time / min	Blank	Assay 1	Assay 2
Before addition	0.118	0.122	0.115
0	0.119	0.169	0.168
5	0.119	0.193	0.199
10	0.119	0.263	0.272
15	0.120	0.355	0.366
20	0.120	0.441	0.453
25	0.120	0.544	0.532
30	0.120	0.667	0.670

15 2.8.5 Determining extinction coefficient of pNP in tritosomal assay conditions

A stock solution of *p*-nitrophenol in DMSO (120mM, 16.69mg/ml) was prepared and a concentration gradient prepared as detailed below. Absorbance was read at 410nm in a chamber incubated at 37°C.

a) Cuvette setup

	Volume / μ l
10mM EDTA	100
50mM GSH	100
120mM <i>p</i> -nitrophenol	As below
Stock solution	740
DMSO	As below

b)

	Vol. <i>p</i> NP/ μ l	Vol. DMSO/ μ l	Actual [pNP]/mM	Absorbance
1	30	0	3.6	1.906
2	22.5	7.5	2.7	1.506
3	15	15	1.8	1.067
4	7.5	22.5	0.9	0.592
5	3	27	0.36	0.314
6	1.5	28.5	0.18	0.223
7	0	30	0.0	0.108

5

2.8.6 Assessment of tritosomal stability of *p*NP- α -L-Rha (a)

A stock solution of *p*-nitrophenyl α -L-rhamnopyranoside in DMSO

(3.1mg/ml, equivalent to BzPheValArgNap solution) was used in an assay

10 equivalent to 2.8.4.

a) Cuvette setup

	Blank – volume / μ l	Assay – volume / μ l
10mM EDTA	100	100
50mM GSH	100	100
Substrate solution	30	30
Stock solution	740	740
Tritosomes	0	30
DMSO	30	0

b) Readings from spectrometer

Time / min	Blank	Assay 1	Assay 2
Before addition	0.112	0.111	0.115
0	0.108	0.158	0.160
5	0.108	0.155	0.159
10	0.108	0.153	0.159
15	0.109	0.151	0.158
20	0.108	0.150	0.159
25	0.108	0.150	0.157
30	0.108	0.149	0.157

2.8.7 Assessment of tritosomal stability of pNP- α -L-Rha (b)

As no activity against α -L-rhamnopyranosides was detected in the previous
 5 assay, a higher concentration of pNP α -L-Rha (31.0mg/ml) in DMSO was used
 in an otherwise identical assay. In addition, the cuvette was incubated at 37°C
 for 20 hours and the absorbance reading repeated.

a) Cuvette setup

	Blank – volume / μ l	Assay – volume / μ l
10mM EDTA	100	100
50mM GSH	100	100
Substrate solution	30	30
Stock solution	740	740
Tritosomes	0	30
DMSO	30	0

10

b) Readings from spectrometer

Time / min	Blank	Assay 1	Assay 2
Before addition	0.126	0.128	0.124
0	0.130	0.173	0.172
5	0.127	0.169	0.170
10	0.127	0.166	0.167
15	0.128	0.165	0.166
20	0.128	0.162	0.164
25	0.128	0.161	0.165
30	0.127	0.158	0.163
20 hours	0.127	0.138	0.131

2.8.8 Assessment of tritosomal stability of *pNP*- β -D-Gal

A stock solution of *p*-nitrophenyl β -D-galactopyranoside in DMSO (31.0
5 mg/ml) was used in an assay equivalent to 2.8.7. In addition, the cuvette was
incubated at 37°C for 20 hours and the absorbance reading repeated.

a) Cuvette setup

	Blank – volume / μ l	Assay – volume / μ l
10mM EDTA	100	100
50mM GSH	100	100
Substrate solution	30	30
Stock solution	740	740
Tritosomes	0	30
DMSO	30	0

10 b) Readings from spectrometer

Time / min	Blank	Assay 1	Assay 2
Before addition	0.125	0.120	0.130
0	0.126	0.170	0.173
5	0.128	0.170	0.173
10	0.126	0.171	0.174
15	0.127	0.172	0.175
20	0.127	0.174	0.175
25	0.126	0.177	0.178
30	0.127	0.180	0.179
20 hours	0.124	0.412	0.402

2.8.9 Assessment of tritosomal stability of *pNP*- β -D-Glc

A stock solution of *p*-nitrophenyl β -D-glucopyranoside in DMSO (31.0
15 mg/ml) was used in an assay equivalent to 2.8.7. In addition, the cuvette was
incubated at 37°C for 20 hours and the absorbance reading repeated.

a) Cuvette setup

	Blank – volume / μ l	Assay – volume / μ l
10mM EDTA	100	100
50mM GSH	100	100
Substrate solution	30	30
Stock solution	740	740
Tritosomes	0	30
DMSO	30	0

b) Readings from spectrometer

Time / min	Blank	Assay 1	Assay 2
Before addition	0.120	0.124	0.122
0	0.124	0.174	0.173
5	0.124	0.171	0.172
10	0.125	0.169	0.171
15	0.125	0.168	0.171
20	0.124	0.168	0.170
25	0.125	0.168	0.168
30	0.126	0.168	0.166
20 hours	0.151	0.331	0.334

5

2.8.10 Determining extinction coefficient of pNP in pH5.5 citrate-phosphate buffer

A stock solution of *p*-nitrophenol (0.2M) in citrate-phosphate buffer (0.2M, pH5.5) was diluted to a series (0.2, 0.1, 0.075, 0.05, 0.025, 0.01, 0.005, 0.0mM) and incubated in a multiwell plate (200 μ l) at 37°C. The absorbance at 405nm was recorded, with and without pathcheck.

2.8.11 Determining standard enzyme kinetics of N-WT in pH5.5 citrate-phosphate buffer

A solution of *p*-nitrophenyl α -L-rhamnopyranoside (3.5mM) in citrate phosphate buffer (0.2M, pH5.5, with and without 0.2% Triton X100) was prepared and diluted into a gradient series (3.5, 3.0, 2.5, 2.0, 1.5, 1.0, 0.5,

0.25mM). A solution of N-WT (5mg/ml) in citrate phosphate buffer (0.2M, pH5.5) was prepared. 190µl substrate solution and 10µl enzyme solution were incubated at 37°C with 5+1second shaking and absorbance at 405nm read every 6 seconds for 5 minutes.

5

2.8.12 Assessment of tritosomal stability of N-WT

N-WT (5mg) was dissolved in citrate phosphate buffer (680µl, 0.2M, pH5.5 plus 1mM EDTA and 5mM GSH) and mixed with Triton X100 solution (20µl, 10%). Tritosome preparation (300µl) was incubated at 37°C for 5 minutes and added to the N-WT solution. Aliquots (50µl) were removed (0, 10, 20, 30, 45, 10 60, 90 minutes, 2, 3, 4, 6, 12, 24, 48 hours) and diluted to a total of 500µl in citrate phosphate buffer and a standard kinetic assay carried out.

15

ⁱ P.R.Crocker, T.Feizi; *Curr.Opin.Struc.Biol.*, 1996, 6, 679-691

ⁱⁱ R.Pulido, F.Sanchezmadrid; *European J.Immunology*, 1992, 22, 463-468

ⁱⁱⁱ P.M.Rudd, R.A.Dwek; *Crit.Rev.Biochem.Mol.Biol.*, 1997, 32, 1-100

^{iv} W.M.Macindoe et al; *Chem.Comm.*, 1998, 847-848

^v I.Niculescu-Duvaz, C.J.Springer; *Adv.Drug.Del.Rev.*, 1997, 26, 151-172

^{vi} P.D.Senter, P.M.Wallace, H.P.Svensson, V.M.Vrudhula, D.E.Kerr, I.Hellström; *Bioconjugate Chem.*, 1993, 4, 3-9

^{vii} P.D.Senter; *FASEB J.*, 1990, 4, 188-193

^{viii} S.K.Sharma; *Adv.Drug.Del.Rev.*, 1996, 22, 369-376

^{ix} S.H.Barondes; *Ann.Rev.Biochem.*, 1981, 50, 207-231

^x For example: N.Sharon, H.Lis; *Trends.Biochem.Sci.*, 1987, 12, 488-491

^{xi} G.Ashwell, J.Harford; *Ann.Rev.Biochem.*, 1982, 51, 531-554

^{xii} P.D.Stahl, J.S.Rodman, M.J.Miller, P.H.Schlesinger; *Proc.Natl.Acad.Sci*, 1978, 75, 1399-1403

-
- ^{xiii} V.L.Shepherd, Y.C.Lee, P.H.Schlesinger, P.D.Stahl; *J.Biol.Chem.*, 1984, **259**, 2257-2261
- ^{xiv} A.C.Roche, P.Midoux, P.Bouchard, M.Monsigny; *FEBS Letters*, 1985, **193**, 63-68
- ^{xv} M.Mutter, G.Beldman, H.A.Schols, A.G.J.Voragen; *Plant Physiol.*, 1994, **106**, 241-250
- ^{xvi} G.Vic, J.J.Hastings, O.W.Haworth, D.H.G.Crout; *Tet.Asymm.*, 1996, **7**, (3), 709-720
- ^{xvii} J.O.Andrianaivoravelona, C.Terreux, S.Sahpaz, J.Rasolondramanitra, K.Hostettmann; *Phytochemistry*, 1999, **52**, 1145-1148
- ^{xviii} M.M.Abou-Zaid, C.Nozzolilli; *Phytochemistry*, 1999, **52**, 1629-1631
- ^{xix} ENZYME online database; <http://www.expasy.ch/enzyme/>
- ^{xx} O.Westphal, H.Feier; *Chem.Ber.*, 1956, 582-588
- ^{xxi} The inventor is grateful to Prof. Ruth Duncan and Miss Samantha Kneller, Cardiff University, for a donation of rat liver tritosome preparation.
- ^{xxii} IODO-GEN technique as described in previous reports
- ^{xxiii} H.Boyd, S.J.Leach, B.Milligan, *Int. J. Peptide Protein Res.*, 1972, **4**, 117-122; Communication from Amersham Biosciences UK
- ^{xxiv} A. Trouet, *Methods Enzymol*, 1974, **31**, 323
- ^{xxv} P.K.Smith, R.I.Krohn, G.T.Hermanson, A.K.Mallia, F.H.Gartner, M.D.Provenzano, E.K.Fujimoto, N.M.Goeke, B.J.Olson, D.C.Klenk, *Anal. Biochem.*, 1985, **150**, 76-85

-104-

CLAIMS

1. A kit for lectin-directed prodrug delivery, comprising a prodrug and a lectin-directed glycoconjugate, wherein the glycoconjugate is adapted to cleave the prodrug
5 and thereby release the drug.
2. A kit according to claim 1 wherein the glycoconjugate comprises an enzyme conjugated to a carbohydrate moiety which binds to a lectin.
- 10 3. A kit according to claim 1 or 2, wherein the carbohydrate is selected from mannose, galactose, glucose, fucose, N-acetylglucosamine and rhamnose.
4. A kit according to claim 1, 2 or 3 wherein the glycoconjugate comprises from 1 to 400 sugar residues.
15
5. A kit according to any one of the preceding claims, wherein the glycoconjugate comprises from 1 to 20 sugar residues per site at from 1 to 20 sites.
6. A kit according to any one of the preceding claims wherein the
20 glycoconjugate comprises an enzyme of the class of rhamnopyranosidases.
7. A kit according to claim 6 wherein the rhamnopyranosidase is an α -L-rhamnopyranosidase.
- 25 8. A kit according to any one of the preceding claims wherein the enzyme is naringinase.
9. A kit according to any one of claims 2 to 8 wherein the carbohydrate is attached to the enzyme through a lysine or cysteine residue.

30

-105-

10. A kit according to any one of claims 2 to 8 wherein the carbohydrate is attached to the enzyme through a linker.

11. A kit according to any one of claims 2 to 8 wherein the carbohydrate is attached to the enzyme through a group selected from the following groups in which - (c) - indicates the linkage to the carbohydrate, - (e) - indicates the linkage to the enzyme, and each n is independently selected from 1 to 10:

(a) an imino alkyl group of the formula Ia

10 Ia - (c) -SCH₂C(NH)- (e) -

or of the formula Ia'

Ia' [- (c) -XCH₂COX(CH₂)_n]2N(CH₂)_nNHCO(CH₂)_nSCH₂C(NH)- (e) -

wherein X is N;

15

(b) a direct link of formula Ib

Ib - (c) - (e) -;

(c) a group of formula Ic

20

Ic -(c)-(CH₂)_nC(O)- (e)- or -(c)-C(O)(CH₂)_n- (e)-; and

(d) a group of formula Id

Id -(c)- CONH(CH₂)_nNH- C(C(O))=C(C(O)) -(e)-


25

wherein - C(C(O))=C(C(O)) - is the 4-membered cyclic squarate.

12. A kit according to any one of claims 2 to 8 wherein the carbohydrate (c) and enzyme (e) comprise a divalent dendrimeric system of general formula II

30


-106-



5 wherein \sim indicates a hydrocarbonyl moiety, X is O, S, CH₂ or NH and n is from 1 to 10.


13. A kit according to claim 12 wherein the carbohydrate (c) and enzyme (e) comprise a divalent dendrimeric system of general formula II'

10



15 wherein each X is independently selected from O, S, CH₂ and NH, each Y is independently selected from NH, S and O, n is from 1 to 10, and the sum of v and v' and of v and v'' independently equals the valence of N, wherein v is 0 or 1 and v' and v'' are independently 1 or 2.

20 14. A kit according to any one of claims 2 to 8 wherein the glycoconjugate is of the formula IIIb



wherein R comprises a carbohydrate, (e) is the enzyme, v and v' are each 1, each n is from 1 to 10 and Y is S.

25

15. A kit according to claim 8 wherein the glycoconjugate is selected from:
 wild type naringinase modified by IME-thiogalactoside reagent;
 wild type naringinase modified by IME-thiomannoside reagent;
 wild type naringinase modified by IME-dendrithiogalactoside reagent;
 30 deglycosylated naringinase, reglycosylated using IME-thiomannoside reagent;
 wild type naringinase modified by IME-thioglycoside reagent;

-107-

wild type naringinase modified by IME-dendrithioglycoside reagent;
deglycosylated naringinase, reglycosylated using IME-thioglycoside reagent; and
deglycosylated naringinase reglycosylated using IME-dendrithioglycoside reagent;
wherein IME is 2-imino-2-methoxyethyl.

5

16. A kit according to any one of the preceding claims wherein the prodrug is a
rhamnoside of an amine, alcohol or thiol.

17. A kit according to any one of the preceding claims for use in a method of
10 therapy practised on the human or animal body.

18. A kit according to claim 17 for use in a method of treating an infectious
disease, a cardiovascular disease, a gastro-intestinal disease, a malignant disease, a
respiratory disease, a musculoskeletal disease or a joint disease.

15

19. A glycoconjugate as defined in any one of claims 1 to 15 and a prodrug for
simultaneous or sequential use in a method of therapy practised on the human or
animal body.

20. Use of a glycoconjugate as defined in any one of claims 1 to 15 for the
manufacture of a medicament for administration sequentially or simultaneously with
a prodrug in the treatment of an infectious disease, a cardiovascular disease, a gastro-
intestinal disease, a malignant disease, a respiratory disease, a musculoskeletal disease
or a joint disease.

25

21. A conjugate comprising a rhamnopyranosidase enzyme glycosylated with
mannose, galactose, glucose, fucose, N-acetylglucosamine, rhamnose or a
combination thereof.

22. A conjugate according to claim 21 which is a monomeric glycosyl conjugate
or a di, poly or dendrimeric glycosyl conjugate.

30

-108-

23. A conjugate according to claim 21 or 22 which is obtainable by deglycosylating a naturally occurring or synthetic rhamnopyranosidase enzyme and then reglycosylating the enzyme with a lectin-binding group.

5

24. A conjugate according to any one of claims 21 to 23, which is of formula Ia, Ib, Ic or Id as defined in claim 11; formula II as defined in claim 12; formula II' as defined in claim 13; or
10 formula IIIb as defined in claim 14; wherein (e) is a rhamnopyranosidase enzyme.

25. A conjugate according to any one of claims 21 to 24 wherein the enzyme is naringinase.

15

26. A conjugate selected from:
wild type naringinase modified by IME-thiogalactoside reagent;
wild type naringinase modified by IME-thiomannoside reagent;
wild type naringinase modified by IME-dendrithiogalactoside reagent;
20 deglycosylated naringinase, reglycosylated using IME-thiomannoside reagent;
wild type naringinase modified by IME-thioglycoside reagent;
wild type naringinase modified by IME-dendrithioglycoside reagent;
deglycosylated naringinase, reglycosylated using IME-thioglycoside reagent; and
deglycosylated naringinase reglycosylated using IME-dendrithioglycoside reagent;
25 wherein IME is 2-imino-2-methoxyethyl.

27. A pharmaceutical composition comprising a conjugate as claimed in any one of claims 21 to 26 and a pharmaceutically acceptable carrier or excipient.

30 28. A conjugate as claimed in any one of claims 21 to 26 for use in a method of therapy practised on the human or animal body.

-109-

29. A method for synthesizing a conjugate as claimed in any one of claims 21 to 25, which method comprises deglycosylating a naturally occurring or synthetic rhamnopyranosidase enzyme and then reglycosylating the enzyme with a lectin-binding group.
30. A method for synthesizing a prodrug comprising a drug moiety and a carbohydrate cap, which comprises contacting the drug in reactive form with a carbohydrate cap donor in the presence of an enzyme.
31. A method according to claim 30 wherein the carbohydrate is an α -rhamnopyranoside and the enzyme is a rhamnopyranosidase.
32. A method according to claim 31 wherein the rhamnopyranosidase is naringinase.
33. A method according to claim 31 or 32 wherein the prodrug is a rhamnoside of an amine, alcohol or thiol.
34. Use of a rhamnopyranosidase enzyme for the production of a prodrug comprising a drug moiety and an α -rhamnopyranoside cap.
35. A use according to claim 34 wherein the rhamnopyranosidase enzyme is naringinase.
36. A method for directing a drug to a cell of a human or animal having a lectin on the surface thereof, which method comprises administering a glycoconjugate as defined in any one of claims 1 to 15 and 21 to 26 simultaneously or sequentially with a prodrug.
37. A pure rhamnopyranosidase enzyme.

-110-

38. A pure enzyme according to claim 37 which is pure naringinase.
39. A pure enzyme according to claim 37 or 38 which has rhamnopyranosidase
5 activity but does not have glucosidase activity.

1/10

Fig.1.





Fig.2.



2/10

Fig.3.





Fig.4.



3/10

Fig.5.





Fig.6.



4/10

Fig.7.





Fig.8.



5/10

Fig.9.





Fig.10.



6/10

Fig.11.






Fig.12.



7/10

Fig.13.



8/10

Fig.14.





Fig.15.



9/10

Fig.16.





Fig.17.



10/10

Fig.18(a).





Fig.18(b).



INTERNATIONAL SEARCH REPORT

International Application No
PCT/GB 02/01613A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 A61K47/48

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, BIOSIS, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	CHASSAGNE D ET AL: "A cyanogenic glycoside from passiflora edulis fruits" PHYTOCHEMISTRY, PERGAMON PRESS, GB, vol. 49, no. 3, October 1998 (1998-10), pages 757-759, XP004290221 ISSN: 0031-9422 page 758, right-hand column, paragraph 1	37, 39
X	PURI M ET AL: "Production, purification, and characterization of the debittering enzyme naringinase" BIOTECHNOLOGY ADVANCES, ELSEVIER PUBLISHING, BARKING, GB, vol. 18, no. 3, May 2000 (2000-05), pages 207-217, XP004202123 ISSN: 0734-9750 the whole document	37-39
-/--		

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents:

A document defining the general state of the art which is not considered to be of particular relevance

E earlier document but published on or after the international filing date

L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

O document referring to an oral disclosure, use, exhibition or other means

P document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

Z document member of the same patent family

Date of the actual completion of the international search

19 June 2002

Date of mailing of the international search report

01/07/2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

G. Willière

INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 02/01613

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	EP 0 187 658 A (GEN HOSPITAL CORP) 16 July 1986 (1986-07-16) the whole document	1-28,36
Y	MELTON ET AL: "Antibody-directed enzyme prodrug therapy (ADEPT). Review article" DRUGS OF THE FUTURE, BARCELONA, ES, vol. 21, no. 2, 1996, pages 167-181, XP002080157 ISSN: 0377-8282 the whole document	1-28,36
Y	WO 99 17806 A (DUGGAN MICHAEL JOHN ;MICROBIOLOGICAL RES AUTHORITY (GB); CHADDOCK) 15 April 1999 (1999-04-15) page 8, line 16 -page 9, line 27	1-28,36
Y	GABOR F ET AL: "Lectin-mediated bioadhesion: binding characteristics of plant lectins on the enterocyte-like cell lines Caco-2, HT-29 and HCT-8" JOURNAL OF CONTROLLED RELEASE, ELSEVIER SCIENCE PUBLISHERS B.V. AMSTERDAM, NL, vol. 55, no. 2-3, 13 November 1998 (1998-11-13), pages 131-142, XP004143508 ISSN: 0168-3659 see especially figure 3 and the abstract	1-28,36

INTERNATIONAL SEARCH REPORT

International application No.
PCT/GB 02/01613

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☒ Claims Nos.: 1, 12, 13 and 24
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 1, 12, 13 and 24

Present claim 1 relates to a kit comprising a glycoconjugate which is defined by reference to a desirable characteristic or property, namely being adapted to cleave a prodrug.

The claim covers all glycoconjugates having this characteristic or property, whereas the application provides support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT for only a very limited number of such adapted glycoconjugates. In the present case, the claim so lacks support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible.

Independent of the above reasoning, the claims also lack clarity (Article 6 PCT). An attempt is made to define the kit by reference to a result to be achieved. Again, this lack of clarity in the present case is such as to render a meaningful search over the whole of the claimed scope impossible. Consequently, the search has been carried out for those parts of the claims which appear to be clear, supported and disclosed, namely those parts relating to glycoconjugates comprising an enzyme conjugated to a carbohydrate moiety which binds to a lectin.

The scope of present claims 1, 12, 13 and 24 lacks clarity because of the incomplete writing/drawing of formulae II and II' (Article 6 PCT).

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

Information on patent family members

In International Application No
PCT/GB 02/01613

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0187658 A	16-07-1986	US 5116613 A	26-05-1992
		AT 129901 T	15-11-1995
		AU 595173 B2	29-03-1990
		AU 5162285 A	17-07-1986
		DE 3650432 D1	14-12-1995
		DE 3650432 T2	18-04-1996
		EP 0187658 A2	16-07-1986
		IL 77533 A	05-11-1990
		JP 2573927 B2	22-01-1997
		JP 61239889 A	25-10-1986
		US 5256413 A	26-10-1993
WO 9917806 A	15-04-1999	AU 741456 B2	29-11-2001
		AU 9357498 A	27-04-1999
		CA 2306350 A1	15-04-1999
		EP 0996468 A1	03-05-2000
		WO 9917806 A1	15-04-1999
		JP 2001518522 T	16-10-2001
		ZA 9809138 A	27-05-1999